Downtime Plans Treatment & Therapy Plans
Loading Documents
- CLL_IP_BENDAMUSTINE_100RITUXIMAB_375_START_ON_DAY_1
- CLL_IP_BENDAMUSTINE_100RITUXIMAB_375_START_ON_DAY_2
- H_39444_BMT_CTN_1503_STRIDE_2_SCREENING_VISIT
- IPOP_RESEARCH_PRO00021862BERNICKER_IMCGP100_ARM_1
- IPOP_RESEARCH_PRO00031115BERNICKER_IMCGP100_TEBENTAFUSP_EXPANDED_ACCESS
- IPOP_RESEARCH_PRO00032110BERNICKER_IMCGP100_TEBENTAFUSP_EXPANDED_ACCESS
- IPOP_RESEARCH_PRO00033129BERNICKER_IMCGP100_TEBENTAFUSP_EXPANDED_ACCESS
- IPOP_RSH_PRO00036343IMCGP100_203ARM_ATEBENTAFUSP
- IPOP_RSH_PRO00036343IMCGP100_203ARM_B
- IPOP_VAC_IE_EVERY_14_DAYS_INTERVAL_COMPRESSED
- IPOP_VAC_IE_EVERY_21_DAYS
- IP_5FU_CONCURRENT_WITH_RADIATION
- IP_5FULEUCOVORIN_EVERY_14_DAYS
- IP_5FUMITOMYCIN_CONCURRENT_WITH_RADIATION
- IP_ABVD
- IP_AC
- IP_AC_DOSE_DENSE
- IP_ADO_TRASTUZUMAB_EMTANSINE
- IP_AIM
- IP_ALEMTUZUMAB
- IP_APL_INDUCTION_LOW_INTERMEDIATE
- IP_APLASTIC_ANEMIA_ATG_CSA
- IP_APML4_FIRST_CONSOLIDATION
- IP_APML4_INDUCTION
- IP_AUGMENTED_CVADPEGASPARGASE_C_VAD_DRUGSPART_AARA_C_MTX_VINC_DRUGSPART_B
- IP_AVDBRENTUXIMAB
- IP_AYA_REMISSION_INDUCTION_CALGB_10403
- IP_AZACITIDINE_5_DAYS
- IP_AZACITIDINE_7_DAYS
- IP_BEACOPP
- IP_BENDAMUSTINEBORTEZOMIBPREDNISONE
- IP_BEP
- IP_BEVACIZUMAB_10MG_KG_EVERY_14_DAYS
- IP_BLINATUMOMAB
- IP_BORTEZOMIB_EVERY_14_DAYS
- IP_BORTEZOMIBDEXAMETHASONE_EVERY_21_DAYS
- IP_BORTEZOMIBDEXAMETHASONE_EVERY_7_DAYS
- IP_BORTEZOMIBDEXAMETHASONECYCLOPHOSHAMIDE
- IP_BRENTUXIMAB_VEDOTIN
- IP_CABAZITAXEL
- IP_CAGT_ALLOGENEIC_SCT_HAPLO_MEL_FLU_WITH_POST_TRANSPLANT_CYCLOPHOSPHAMIDE
- IP_CAGT_ALLOGENEIC_SCT_BU_CY_WITH_TACROLIMUS_AND_MINI_METHOTREXATE_GVHD_PROPHYLAXIS
- IP_CAGT_ALLOGENEIC_SCT_BU_FLU_WITH_TACROLIMUS_AND_MINI_METHOTREXATE_GVHD_PROPHYLAXIS
- IP_CAGT_ALLOGENEIC_SCT_CAMGRAFT
- IP_CAGT_ALLOGENEIC_SCT_CY_TBI
- IP_CAGT_ALLOGENEIC_SCT_CY_TBI_CAM
- IP_CAGT_ALLOGENEIC_SCT_FLU_MEL_WITH_TACROLIMUS_AND_MINI_METHOTREXATE_GVHD_PROPHYLAXIS
- IP_CAGT_ALLOGENEIC_SCT_FLU_MEL_CAM
- IP_CAGT_ALLOGENEIC_SCT_FLU_MEL_PTCY
- IP_CAGT_ALLOGENEIC_SCT_IV_BU_CY_CAM
- IP_CAGT_ALLOGENEIC_SCT_IV_BU_FLU_CAM
- IP_CAGT_ALLOGENEIC_SCT_IV_BU_FLU_PTCY
- IP_CAGT_ALLOGENEIC_SCT_IV_CLO_BU_CAM
- IP_CAGT_ALLOGENEIC_SCT_SAAHAPLO_ATGRABBIT_CY_FLU_TBI_PTCY
- IP_CAGT_ALLOGENEIC_SCT_SAAMUD
- IP_CAGT_AUTOLOGOUS_MOBILIZATION_CYTARABINE
- IP_CAGT_AUTOLOGOUS_MOBILIZATION_HIGH_DOSE_CYCLOPHOSPHAMIDE
- IP_CAGT_AUTOLOGOUS_SCT_HIGH_DOSE_ETOPOSIDECARBOPLATIN_EINHORN_PROTOCOL
- IP_CAGT_AUTOLOGOUS_SCT_HIGH_DOSE_ETOPOSIDECARBOPLATIN_TICE_PROTOCOL
- IP_CAGT_AUTOLOGOUS_SCT_HIGH_DOSE_MELPHALAN
- IP_CAGT_AUTOLOGOUS_SCT_IV_BEAM
- IP_CAGT_AUTOLOGOUS_SCT_IV_BEAM_R
- IP_CAGT_AUTOLOGOUS_SCT_IV_CARMUSTINETHIOTEPA_MATRIX
- IP_CAGT_R_IE
- IP_CARBOPLATIN_AUC_6DOCETAXEL_75_MG_M2
- IP_CARBOPLATIN_AUC_2GEMCITABINE_EVERY_21_DAYS
- IP_CARBOPLATIN_AUC_4GEMCITABINE_1000BEVACIZUMAB_15
- IP_CARBOPLATIN_AUC_5GEMCITABINE_1000_MG_M2
- IP_CARBOPLATIN_AUC_5LIPOSOMAL_DOXORUBICIN_30
- IP_CARBOPLATIN_AUC_6PACLITAXEL_175_GYNECOLOGIC
- IP_CARBOPLATINETOPOSIDE_EVERY_21_DAYS
- IP_CARBOPLATINGEMCITABINE
- IP_CARBOPLATINNAB_PACLITAXEL
- IP_CARBOPLATINPACLITAXEL_DOSE_DENSE
- IP_CARBOPLATINPACLITAXEL_LUNG
- IP_CARBOPLATINPACLITAXELBEVACIZUMAB
- IP_CARBOPLATINPACLITAXELBEVACIZUMAB_DOSE_DENSE
- IP_CARBOPLATINPACLITAXEL_W_CONCURRENT_THORACIC_RT
- IP_CARBOPLATINPEMETREXED
- IP_CARBOPLATINPEMETREXEDBEVACIZUMAB
- IP_CARBOPLATIN_DESENSITIZATION
- IP_CARFILZOMIB_INITIAL_CYCLE
- IP_CARFILZOMIB_MAINTENANCE
- IP_CEOP
- IP_CETUXIMAB_EVERY_14_DAYS
- IP_CETUXIMAB_INITIAL_DOSE_EVERY_7_DAYS
- IP_CETUXIMAB_MAINTENANCE_DOSE_EVERY_7_DAYS
- IP_CHOP
- IP_CIA
- IP_CISPLATINDOCETAXEL_EVERY_21_DAYS
- IP_CISPLATINDOCETAXEL5FU
- IP_CISPLATINDOXORUBICIN
- IP_CISPLATINDOXORUBICIN_DEXRAZOXANE
- IP_CISPLATINETOPOSIDE_EVERY_21_DAYS
- IP_CISPLATINETOPOSIDE_W_CONCURRENT_THORACIC_RT_EVERY_21_DAYS
- IP_CISPLATINGEMCITABINE_EVERY_21_DAYS
- IP_CISPLATINGEMCITABINE_EVERY_28_DAYS
- IP_CISPLATINIRINOTECAN_EVERY_21_DAYS_D1_D8
- IP_CISPLATINPACLITAXEL
- IP_CISPLATINPACLITAXEL_INTRAPERITONEAL
- IP_CISPLATINPACLITAXELBEVACIZUMAB
- IP_CISPLATINPEMETREXED
- IP_CISPLATINPEMETREXED_W_CONCURRENT_THORACIC_RT
- IP_CISPLATINVINORELBINE_EVERY_21_DAYS
- IP_CISPLATIN_20_MG_M2_EVERY_7_DAYS
- IP_CISPLATIN_25_MG_M2_EVERY_7_DAYS
- IP_CISPLATIN_60ETOPOSIDE_100_EVERY_21_DAYS
- IP_CISPLATIN_75_MG_M2_EVERY_21_DAYS
- IP_CISPLATIN_W_CONCURRENT_RT_EVERY_7_DAYS
- IP_CLADRIBINE_0.09_7_DAYS
- IP_CLADRIBINE_0.14_DAILY
- IP_CLADRIBINE_0.15_WEEKLY
- IP_CLAG
- IP_CLIA
- IP_CLOFARABINECYTARABINE
- IP_CODOX_A
- IP_CODOX_B
- IP_CYBORDEX
- IP_CYCLOPHOSPHAMIDEFLUDARABINELIFILEUCELHIGH_DOSE_IL_2
- IP_CYCLOPHOSPHAMIDEVINCRISTINEMERCAPTOPURINECYTARABINEPEGASPARGASE
- IP_CYTARABINEDAUNORUBICINGEMTUZUMAB_7_3
- IP_CYTARABINEIDARUBICIN_7_3
- IP_CYTARABINE_100DAUNORUBICIN_60_7_3
- IP_DARATUMUMAB
- IP_DEANGELIS_METHOTREXATEVINCRISTINELEUCOVORINPROCARBAZINE_CYCLES_1_3_5
- IP_DEANGELIS_WITH_RITUXIMAB_METHOTREXATEVINCRISTINELEUCOVORIN_CYCLES_2_AND_4
- IP_DEANGELIS_WITH_RITUXIMAB_METHOTREXATEVINCRISTINELEUCOVORINPROCARBAZINE_CYCLES_1_3_5
- IP_DECITABINE_28_DAYS
- IP_DECITABINE_42_DAYS
- IP_DHAP
- IP_DOCETAXEL
- IP_DOCETAXELCAPECITABINE
- IP_DOCETAXEL_30_MG_M2_EVERY_21_DAYS
- IP_DOCETAXEL_75_MG_M2_EVERY_21_DAYS
- IP_DOF_DOCETAXELOXALIPLATINFLUOROURACIL_EVERY_14_DAYS
- IP_EC_100_830
- IP_EC_75_600
- IP_EOF_EPIRUBICINOXALIPLATINFLUOROURACIL
- IP_EP
- IP_EPOCH
- IP_ERIBULIN
- IP_ESHAP
- IP_FEC_EVERY_21_DAYS
- IP_FLAG_IDA
- IP_FLAG_IDA_CONSOLIDATION
- IP_FLAT_DOSE_CYTARABINE
- IP_FLUDARABINECYCLOPHOSPHAMIDERITUXIMAB
- IP_FOLFIRI_EVERY_14_DAYS
- IP_FOLFIRIBEVACIZUMAB_EVERY_14_DAYS
- IP_FOLFIRICETUXIMAB_INITIAL_DOSE_EVERY_14_DAYS
- IP_FOLFIRICETUXIMAB_400_MG_M2_EVERY_14_DAYS
- IP_FOLFIRICETUXIMAB_500_MG_M2_EVERY_14_DAYS
- IP_FOLFIRIPANITUMUMAB
- IP_FOLFIRIRAMUCIRUMAB
- IP_FOLFIRIZIV_AFLIBERCEPT_EVERY_14_DAYS
- IP_FOLFIRINOX_EVERY_14_DAYS
- IP_FOLFOXIRI_EVERY_14_DAYS
- IP_FOLFOXIRI_EVERY_14_DAYS_WITH_CETUXIMAB_DAY_1_AND_DAY_8
- IP_FOLFOXIRIBEVACIZUMAB_EVERY_14_DAYS
- IP_FOLFOXIRICETUXIMAB_EVERY_14_DAYS
- IP_FOLFOXIRIPANITUMUMAB_EVERY_14_DAYS
- IP_FOLFOXIRIZIV_AFLIBERCEPT_EVERY_14_DAYS
- IP_GDP
- IP_GEMCITABINECISPLATIN_EVERY_21_DAYS
- IP_GEMCITABINECISPLATIN_EVERY_21_DAYS_LUNG
- IP_GEMCITABINECISPLATIN_SPLIT_DOSE
- IP_GEMCITABINEDOCETAXEL
- IP_GEMCITABINEVINORELBINEDOXORUBICIN_LIPOSOMAL
- IP_GEMCITABINE_1000_EVERY_28_DAYS
- IP_GEMCITABINE_1000_MG_M2_EVERY_21_DAYS
- IP_GEMCITABINE_675_EVERY_28_DAYS
- IP_GEMCITABINE_800_EVERY_7_DAYS
- IP_GEMCITABINE_800_MG_M2_EVERY_21_DAYS
- IP_GEMOX_675_80
- IP_HIDAC_D1_3_5
- IP_HIDAC_D1_3_5DAUNORUBICIN
- IP_HIDAC_D1_3_5IDARUBICIN
- IP_HIGH_DOSE_METHOTREXATELEUCOVORIN_DAY_2
- IP_HYPERCVAD_A_AND_B_ALTERNATING
- IP_ICE
- IP_IFOSFAMIDEETOPOSIDE
- IP_INOTUZUMAB_OZOGAMICIN_CONSOLIDATION
- IP_INOTUZUMAB_OZOGAMICIN_INDUCTION
- IP_INTRATHECAL_CHEMOTHERAPY
- IP_IRINOTECANCETUXIMABVEMURAFENIB_EVERY_14_DAYS
- IP_IROX
- IP_IXABEPILONE
- IP_LIPOSOMAL_DOXORUBICIN_EVERY_14_DAYS
- IP_LIPOSOMAL_DOXORUBICIN_EVERY_28_DAYS
- IP_LIPOSOMAL_DOXORUBICINBEVACIZUMAB
- IP_LIPOSOMAL_IRINOTECANLEUCOVORINFLUOROURACIL
- IP_MEC_5_DAYS
- IP_MFOLFOX6_EVERY_14_DAYS
- IP_MFOLFOX6_EVERY_14_DAYSCETUXIMAB_D1__8
- IP_MFOLFOX6BEVACIZUMAB_EVERY_14_DAYS
- IP_MFOLFOX6CETUXIMAB_EVERY_14_DAYS
- IP_MFOLFOX6CETUXIMAB_LOADING_DOSE_EVERY_7_DAYS_14_DAY_CYCLE
- IP_MFOLFOX6PANITUMUMAB
- IP_MFOLFOX6ZIV_AFLIBERCEPT_EVERY_14_DAYS
- IP_MINICHOP
- IP_MODIFIED_CYBORDEX
- IP_MODIFIED_FOLFIRINOX_EVERY_2_WEEKS
- IP_MOXETUMOMAB_EVERY_28_DAYS
- IP_MVAC_DOSE_DENSE
- IP_NAB_PACLITAXEL
- IP_NAB_PACLITAXEL_EVERY_7_DAYS
- IP_NAB_PACLITAXELGEMCITABINE
- IP_NAB_PACLITAXELGEMCITABINE_DOSE_REDUCED_EVERY_28_DAYS
- IP_O_FC_CYCLE_1_ONLY
- IP_O_FC_CYCLE_2_AND_BEYOND
- IP_OBINUTUZUMABCHLORAMBUCIL_CYCLE_1_ONLY
- IP_OFATUMUMAB_CYCLE_1_ONLY
- IP_OFATUMUMAB_WEEKLY_REFRACTORY
- IP_OXALIPLATIN_DESENSITIZATION
- IP_PACLITAXEL_DOSE_DENSE_EVERY_21_DAYS
- IP_PACLITAXEL_80_EVERY_21_DAYS
- IP_PACLITAXEL_80_EVERY_28_DAYS
- IP_PACLITAXEL_80_EVERY_7_DAYS
- IP_PAD
- IP_PANITUMUMAB
- IP_PEMETREXED
- IP_PENTOSTATIN
- IP_PRALATREXATE
- IP_PRO00037588_IOV_GM1_201_GANGULY
- IP_R_CEOP
- IP_R_CHOP
- IP_R_CVP
- IP_R_DHAP
- IP_R_EPOCH
- IP_R_ESHAP
- IP_R_HIGH_DOSE_METHOTREXATE_LEUCOVORIN_DAY_2
- IP_R_HYPERCVAD_A_AND_B_ALTERNATING
- IP_R_ICE
- IP_R_MINICHOP
- IP_RAMUCIRUMAB_EVERY_14_DAYS
- IP_RAMUCIRUMABDOCETAXEL_EVERY_21_DAYS
- IP_RAMUCIRUMABPACLITAXEL_EVERY_28_DAYS
- IP_RESEARCHHILL_CTL_H_43761_CRIMSON_NE
- IP_RESEARCHHILL_H_48389_ALTRUBIO_MULTIPLE_DOSE_PK_SUBJECTS
- IP_RESEARCHHILL_H_48389_ALTRUBIO_MULTIPLE_DOSE_RETREATMENT
- IP_RESEARCHHILL_H_48389_ALTRUBIO_MULTIPLE_DOSE_PHASE
- IP_RESEARCH_BMT_CTN_1705_H_46470
- IP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_B_FIT_PATIENTS_AGES_18_70_SHAH
- IP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_C_INTENSIFICATION_SHAH
- IP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_E_FIT_PATIENTS_AGES_18_70_SHAH
- IP_RITUXIMAB_375_WEEKLY
- IP_RITUXIMAB_375BORTEZOMIB_CYCLE_1_ONLY
- IP_RITUXIMAB_375BORTEZOMIB_CYCLE_2_AND_BEYOND
- IP_ROMIDEPSIN
- IP_TAC
- IP_TC
- IP_TCH_LOADING_DOSE_ONLY
- IP_TCH_MAINTENANCE_REGIMEN
- IP_TECLISTAMAB_CQYV
- IP_TEMOZOLOMIDERITUXIMAB
- IP_TFOX_EVERY_14_DAYS
- IP_TIP_GERM_CELL_TUMORS
- IP_TOPOTECAN_DAILY
- IP_TOPOTECAN_EVERY_21_DAYS_D1_D8_D15
- IP_TOPOTECAN_WEEKLY
- IP_TOPOTECANBEVACIZUMAB
- IP_TOPOTECANBEVACIZUMAB_EVERY_7_DAYS
- IP_TRABECTEDIN
- IP_TRASTUZUMAB_EVERY_21_DAYS_LOADING_DOSE
- IP_TRASTUZUMAB_EVERY_7_DAYS
- IP_TRASTUZUMABLAPATINIB_CYCLE_1_ONLY
- IP_TRASTUZUMABLAPATINIB_CYCLE_2_AND_BEYOND
- IP_TRASTUZUMABPACLITAXEL_EVERY_7_DAYS
- IP_TRASTUZUMABPERTUZUMABDOCETAXEL_CYCLE_1_ONLY
- IP_TRASTUZUMABPERTUZUMABDOCETAXEL_CYCLE_2_AND_BEYOND
- IP_TRASTUZUMABPERTUZUMABDOCETAXELCARBOPLATIN_LOADING_DOSE_ONLY
- IP_TRASTUZUMABPERTUZUMABDOCETAXELCARBOPLATIN_MAINTENANCE_REGIMEN
- IP_TRASTUZUMABPERTUZUMABPACLITAXEL_CYCLE_1_ONLY
- IP_TRASTUZUMABPERTUZUMABPACLITAXEL_CYCLE_2_AND_BEYOND
- IP_TRASTUZUMAB_6_EVERY_21_DAYS_MAINTENANCE_DOSE
- IP_V_DCEP
- IP_VAC_ALTERNATING_WITH_IE
- IP_VAD
- IP_VD_PACE
- IP_VINCRISTINE_EVERY_28_DAYS
- IP_VINORELBINE_EVERY_7_DAYS
- IP_VIP
- IP_VYXEOS_CONSOLIDATION
- IP_VYXEOS_INDUCTION
- IP_WEEKLY_IRINOTECANFLUOROURACILLEUCOVORIN_EVERY_28_DAYS
- IP_XELIRI_EVERY_21_DAYS
- IP_XELIRIBEVACIZUMAB_EVERY_21_DAYS
- IP_XELIRICETUXIMAB_EVERY_21_DAYS
- IP_XELIRIPANITUMUMAB
- IP_XELIRIZIV_AFLIBERCEPT
- IP_XELOX_EVERY_21_DAYS
- IP_XELOX_EVERY_21_DAYS_CETUXIMAB_D1__8__15
- IP_XELOX_BEVACIZUMAB_EVERY_21_DAYS
- IP_XELOXZIV_AFLIBERCEPT_EVERY_21_DAYS
- IP_OP_BIWEEKLY_TALQUETAMAB_TGVS_TALVEY
- IP_OP_EMA_CO
- IP_OP_HYPERFRACTIONATED_CYCLOPHOSPHAMIDE
- IP_OP_RESEARCH_PRO00035531GANGULY_TNB383B.0001_PHASE_I_ARM_E
- IP_OP_RESEARCH_PRO00035735_ANHL1931_PINGALI_ARM_A
- IP_OP_RESEARCH_PRO00035735_ANHL1931_PINGALI_ARM_B
- IP_OP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_C_SHAH
- IP_OP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_D_SHAH
- IP_OP_RESEARCH_PRO00037627GANGULY_P_BCMA_ALL01_OPEN_LABEL__PHASE_I_ARM_P1
- IP_OP_RESEARCH_PRO00037627GANGULY_P_BCMA_ALL01_OPEN_LABEL__PHASE_I_ARM_P1.5
- IP_OP_RESEARCH_PRO00037922GANGULY_PFIZER_C1071032_OPEN_LABEL_ELRANATAMAB_ARM_A
- IP_OP_RSH_CILESTE_H_47906
- IP_OP_RSH_PRO00035986EA9152ARM_D
- IP_OP_TARLATAMAB_DLLE
- IP_OP_TEBENTAFUSP_TEBN
- IP_OP_WEEKLY_TALQUETAMAB_TGVS_TALVEY
- NHL_IP_BENDAMUSTINE_120RITUXIMAB_375_START_ON_DAY_1
- NHL_IP_BENDAMUSTINE_120RITUXIMAB_375_START_ON_DAY_2
- NHL_IP_BENDAMUSTINE_90RITUXIMAB_375_START_ON_DAY_1
- NHL_IP_BENDAMUSTINE_90RITUXIMAB_375_START_ON_DAY_2
- OP_5FULEUCOVORIN_EVERY_14_DAYS
- OP_5FUMITOMYCIN_CONCURRENT_WITH_RADIATION
- OP_5FU_CONTINUOUS_INFUSION_CONCURRENT_WITH_RADIATION
- OP_ABVD
- OP_AC
- OP_AC_DOSE_DENSE
- OP_AC_PEMBROLIZUMAB
- OP_ADO_TRASTUZUMAB_EMTANSINE_CYCLE_1_AND_CYCLE_2_4
- OP_AIM
- OP_ALEMTUZUMAB
- OP_AMIVANTAMAB_VMJW
- OP_APML4_MAINTENANCE
- OP_APML4_SECOND_CONSOLIDATION
- OP_ARSENIC_TRIOXIDE_CONSOLIDATION
- OP_ARSENIC_TRIOXIDE_INDUCTION
- OP_ARSENIC_TRIOXIDE_MAINTENANCE_EVERY_28_DAYS
- OP_ATEZOLIZUMABBEVACIZUMAB_EVERY_21_DAYS
- OP_ATEZOLIZUMABNAB_PACLITAXEL_EVERY_28_DAYS
- OP_ATEZOLIZUMAB_1200_MG_EVERY_21_DAYS
- OP_ATEZOLIZUMAB_1680_MG_EVERY_28_DAYS
- OP_AVDBRENTUXIMAB
- OP_AVELUMAB_Q14_DAYS
- OP_AYA_COURSE_1_REMISSION_INDUCTION
- OP_AYA_COURSE_1A_EXTENDED_REMISSION_INDUCTION
- OP_AYA_COURSE_2_REMISSION_CONSOLIDATION
- OP_AYA_COURSE_3_INTERIM_MAINTENANCE
- OP_AYA_COURSE_4_DELAYED_INTENSIFICATION
- OP_AYA_COURSE_5_MAINTENANCE_THERAPY
- OP_AZACITIDINE_5_DAYS
- OP_AZACITIDINE_7_DAYS
- OP_BCG_VIA_FOLEY_CATHETER_FOR_LOW_TO_IMMEDIATE_RISK_LOCALIZED_UROTHELIAL_CANCER
- OP_BCG_VIA_NEPHROSTOMY_TUBE
- OP_BEACOPP
- OP_BELANTAMAB_MAFODOTIN_BLMF_EVERY_21_DAYS
- OP_BELINOSTAT
- OP_BENDAMUSTINEBORTEZOMIBPREDNISONE
- OP_BENDAMUSTINERITUXIMAB_DAY_1_START_CLL
- OP_BENDAMUSTINERITUXIMAB_DAY_1_START_NHL_EVERY_21_DAYS
- OP_BENDAMUSTINERITUXIMAB_DAY_1_START_NHL_EVERY_28_DAYS
- OP_BENDAMUSTINERITUXIMAB_DAY_2_START_CLL
- OP_BENDAMUSTINERITUXIMAB_DAY_2_START_NHL_EVERY_21_DAYS
- OP_BENDAMUSTINERITUXIMAB_DAY_2_START_NHL_EVERY_28_DAYS
- OP_BEP
- OP_BEVACIZUMAB_10_EVERY_14_DAYS
- OP_BEVACIZUMAB_15_EVERY_21_DAYS
- OP_BICNU__CISPLATIN_AND_VINCRISTINE_FOR_MEDULLOBLASTOMA
- OP_BLANK_CHEMOTHERAPY_PROTOCOL_TEMPLATE
- OP_BORTEZOMIB_EVERY_21_DAYS
- OP_BORTEZOMIB_EVERY_7_DAYS
- OP_BORTEZOMIBLIPOSOMAL_DOXORUBICIN
- OP_BORTEZOMIB_MAINTENANCE_EVERY_14_DAYS
- OP_BRENTUXIMAB_VEDOTIN
- OP_CABAZITAXEL
- OP_CAGT_AUTOLOGOUS_MOBILIZATION_HIGH_DOSE_CYCLOPHOSPHAMIDE
- OP_CAGT_AUTOLOGOUS_SCT_IV_RITUXIMAB_BEAM_R
- OP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINE
- OP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINETISAGENLECLEUCEL_ACUTE_LYMPHOCYTIC_LEUKEMIA_ALL
- OP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINETISAGENLECLEUCEL_DIFFUSE_LARGE_B_CELL_LYMPHOMA_DLBCL
- OP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINE_LYMPHODEPLETION_–_MAGENTA
- OP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINE_LYMPHODEPLETION_–_RELY_30
- OP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINE_LYMPHODEPLETION_–_VEGAS
- OP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINE_NIVOLUMAB_LYMPHODEPLETION_–_HESTIA
- OP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_AXICABTAGENE_CILOLEUCEL–_DIFFUSE_LARGE_B_CELL_LYMPHOMA_DLBCL
- OP_CAGT_NIVOLUMAB_–_PREVALE
- OP_CAGT_R_IE
- OP_CAP
- OP_CAPECITABINE
- OP_CARBOPLATIN_AUC_2NAB_PACLITAXEL_DAY_1_AND_8_ONLYPEMBROLIZUMAB
- OP_CARBOPLATIN_AUC_4GEMCITABINE
- OP_CARBOPLATIN_AUC_5ETOPOSIDEATEZOLIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_5GEMCITABINE
- OP_CARBOPLATIN_AUC_5GEMCITABINENIVOLUMAB_LUNG_CANCER
- OP_CARBOPLATIN_AUC_5PACLITAXEL_BREAST
- OP_CARBOPLATIN_AUC_5WEEKLY_PACLITAXELPEMBROLIZUMAB
- OP_CARBOPLATIN_AUC_6PACLITAXELBEVACIZUMABATEZOLIZUMAB
- OP_CARBOPLATIN_AUC_6PACLITAXELNIVOLUMAB_LUNG_CANCER
- OP_CARBOPLATIN_AUC_6PACLITAXELPEMBROLIZUMAB_CYCLE_1_4_FOLLOWED_BY_PEMBROLIZUMAB
- OP_CARBOPLATINCETUXIMAB
- OP_CARBOPLATINDOCETAXEL
- OP_CARBOPLATINETOPOSIDE_EVERY_21_DAYS
- OP_CARBOPLATINETOPOSIDE_W_ACC_HYPERFX_RADIATION
- OP_CARBOPLATINGEMCITABINE_EVERY_7_DAYS
- OP_CARBOPLATINGEMCITABINEBEVACIZUMAB
- OP_CARBOPLATINLIPOSOMAL_DOXORUBICIN
- OP_CARBOPLATINNAB_PACLITAXEL
- OP_CARBOPLATINNAB_PACLITAXELPEMBROLIZUMAB
- OP_CARBOPLATINPACLITAXEL_DOSE_DENSE
- OP_CARBOPLATINPACLITAXEL_GYNECOLOGIC
- OP_CARBOPLATINPACLITAXEL_LUNG
- OP_CARBOPLATINPACLITAXELBEVACIZUMAB
- OP_CARBOPLATINPACLITAXELBEVACIZUMAB_DOSE_DENSE
- OP_CARBOPLATINPACLITAXEL_W_CONCURRENT_THORACIC_RT
- OP_CARBOPLATINPEMETREXED
- OP_CARBOPLATINPEMETREXEDBEVACIZUMAB
- OP_CARBOPLATIN_AUC_4CABAZITAXEL
- OP_CARBOPLATIN_W_CONCURRENT_THORACIC_RT
- OP_CARFILZOMIB_INITIAL_AND_MAINTENANCE
- OP_CARFILZOMIB_INITIAL_CYCLE
- OP_CARFILZOMIB_MAINTENANCE
- OP_CARFILZOMIB_WEEKLY
- OP_CARMUSTINEBEVACIZUMAB_EVERY_42_DAYS
- OP_CEMIPLIMAB_EVERY_21_DAYS
- OP_CEOP
- OP_CETUXIMAB_EVERY_14_DAYS
- OP_CETUXIMAB_EVERY_2_WEEKSPEMBROLIZUMAB_EVERY_6_WEEKS
- OP_CETUXIMAB_EVERY_7_DAYS
- OP_CHOEP_EVERY_21_DAYS
- OP_CHOP
- OP_CIA
- OP_CISPLATIN_EVERY_21_DAYS
- OP_CISPLATINCETUXIMAB
- OP_CISPLATINDOCETAXEL_EVERY_21_DAYS
- OP_CISPLATINDOCETAXEL5FU
- OP_CISPLATINDOXORUBICIN
- OP_CISPLATINETOPOSIDE_EVERY_21_DAYS_60_100
- OP_CISPLATINETOPOSIDE_EVERY_21_DAYS_75_100
- OP_CISPLATINETOPOSIDE_W_CONCURRENT_THORACIC_RT_EVERY_21_DAYS
- OP_CISPLATINETOPOSIDE_W_CONCURRENT_THORACIC_RT_EVERY_28_DAYS
- OP_CISPLATINGEMCITABINE_EVERY_28_DAYS
- OP_CISPLATINIRINOTECAN_EVERY_21_DAYS_D1_D8
- OP_CISPLATINIRINOTECAN_EVERY_21_DAYS_D1_D8_D15
- OP_CISPLATINPACLITAXEL
- OP_CISPLATINPACLITAXELBEVACIZUMAB
- OP_CISPLATINPEMETREXED
- OP_CISPLATINPEMETREXEDNIVOLUMAB_LUNG_CANCER
- OP_CISPLATINPEMETREXED_W_CONCURRENT_THORACIC_RT
- OP_CISPLATINVINORELBINE_EVERY_21_DAYS
- OP_CISPLATIN_20_MG_M2_EVERY_7_DAYS
- OP_CISPLATIN_25_MG_M2_EVERY_7_DAYS
- OP_CISPLATIN_W_CONCURRENT_RT_EVERY_21_DAYS
- OP_CISPLATIN_W_CONCURRENT_RT_EVERY_7_DAYS
- OP_CLADRIBINE_DAILY
- OP_CLADRIBINE_WEEKLY
- OP_CLOFARABINECYTARABINE
- OP_CMF
- OP_COPP
- OP_CVP
- OP_CYBORDEX
- OP_CYCLOPHOSPHAMIDEVINCRISTINEMERCAPTOPURINECYTARABINEPEGASPARGASE
- OP_DARATUMUMAB
- OP_DARATUMUMABBORTEZOMIBDEXAMETHASONE
- OP_DARATUMUMAB_HYALURONIDASE_DARZALEX_FASPRO
- OP_DARATUMUMAB_HYALURONIDASE_FIHJ_BORTEZOMIBDEXAMETHASONE_GRIFFIN_TRIAL
- OP_DARATUMUMAB_HYALURONIDASE_FIHJCARFILZOMIBDEXAMETHASONE_CANDOR_TRIAL_EVERY_28_DAYS
- OP_DARZALEX_FASPRO_CYBORDEX_ANDROMEDA_PROTOCOL
- OP_DARZALEX_FASPRO_CYBORDEX_LYRA_PROTOCOL
- OP_DECITABINE_28_DAYS
- OP_DECITABINE_42_DAYS
- OP_DOCETAXEL
- OP_DOCETAXEL_EVERY_21_DAYS
- OP_DOCETAXELCAPECITABINE
- OP_DOXORUBICIN_75_MG_M2_BOLUS_IFOSFAMIDE_10_G_M2_OVER_4_DAYS_MESNA_CIV
- OP_DOXORUBICIN_75_MG_M2_BOLUS_IFOSFAMIDE_10_G_M2_OVER_5_DAYS_MESNA_BOLUS
- OP_DOXORUBICIN_75_MG_M2_CIV_IFOSFAMIDE_10_G_M2_OVER_5_DAYS_MESNA_BOLUS
- OP_DOXORUBICIN_TRABECTEDIN_INDUCTION
- OP_DURVALUMAB_FLAT_DOSE_1500_MG_EVERY_4_WEEKS
- OP_DURVALUMAB_WEIGHT_BASED_DOSE_EVERY_14_DAYS
- OP_DURVALUMAB_GEMCITABINE_CISPLATIN_X_8_CYCLES_EVERY_21_DAYS_THEN_DURVALUMAB_MAINTENANCE_EVERY_28_DAYS_CHOLANGIOCARCINOMA
- OP_DVD_LOW_DOSE
- OP_DVD_R
- OP_EC_100_830
- OP_EC_75_600
- OP_ELOTUZUMAB
- OP_ENFORTUMAB_VEDOTINPEMBROLIZUMAB_EVERY_21_DAYS
- OP_ENFORTUMAB_VEDOTIN_EJFV_EVERY_28_DAYS
- OP_EOF
- OP_EP
- OP_ERIBULIN
- OP_ETOPOSIDECISPLATINCYCLOPHOSPHAMIDE
- OP_FAC_EVERY_21_DAYS
- OP_FAM_TRASTUZUMAB_DERUXTECAN_EVERY_21_DAYS
- OP_FAM_TRASTUZUMAB_DERUXTECAN_EVERY_21_DAYS_FOR_GI_MALIGNANCY
- OP_FEC_EVERY_21_DAYS
- OP_FLA
- OP_FLAG_IDA
- OP_FLOT
- OP_FLUDARABINECYCLOPHOSPHAMIDERITUXIMAB
- OP_FOLFIRI_EVERY_14_DAYS
- OP_FOLFIRIBEVACIZUMAB_EVERY_14_DAYS
- OP_FOLFIRICETUXIMAB_EVERY_14_DAYS
- OP_FOLFIRICETUXIMAB_EVERY_7_DAYS
- OP_FOLFIRIPANITUMUMAB
- OP_FOLFIRIRAMUCIRUMAB
- OP_FOLFIRIZIV_AFLIBERCEPT_EVERY_14_DAYS
- OP_FOLFOX_PLUS_XRT_ESOPHAGEAL_CANCER_DEFINITIVE_CHEMORADIATION
- OP_FOLFOXIRI_EVERY_14_DAYS
- OP_FOLFOXIRI_EVERY_14_DAYSCETUXIMAB_EVERY_7_DAYS
- OP_FOLFOXIRIBEVACIZUMAB_EVERY_14_DAYS
- OP_FOLFOXIRICETUXIMAB_EVERY_14_DAYS
- OP_FOLFOXIRIPANITUMUMAB_EVERY_14_DAYS
- OP_FOLFOXIRIZIV_AFLIBERCEPT_EVERY_14_DAYS
- OP_FULVESTRANT_INITIAL_AND_MAINTENANCE
- OP_GDP
- OP_GEMCITABINE_EVERY_21_DAYS
- OP_GEMCITABINE_EVERY_28_DAYS
- OP_GEMCITABINECISPLATIN_EVERY_21_DAYS_LUNG
- OP_GEMCITABINECISPLATIN_EVERY_21_DAYS_UROTHELIAL_BLADDER
- OP_GEMCITABINECISPLATIN_GALLBLADDER
- OP_GEMCITABINECISPLATIN_SPLIT_DOSE_UROTHELIAL_BLADDER
- OP_GEMCITABINECISPLATINNECITUMUMAB_EVERY_21_DAYS
- OP_GEMCITABINEDOCETAXEL
- OP_GEMCITABINEVINORELBINEDOXORUBICIN_LIPOSOMAL
- OP_GEMCITABINE_1000_EVERY_7_DAYS
- OP_GEMCITABINE_675
- OP_GEMOX_1000_100_EVERY_14_DAYS
- OP_GEMOX_675_80
- OP_GEMOX_R_1000_100_EVERY_14_DAYS
- OP_IBRITUMOMAB_ZEVALIN_Y_90
- OP_IFOSFAMIDE_XRT
- OP_INOTUZUMAB_OZOGAMICIN_CONSOLIDATION
- OP_INOTUZUMAB_OZOGAMICIN_INDUCTION
- OP_INTRATHECAL_CHEMOTHERAPY
- OP_INTRAVESICAL_GEMCITABINEDOCETAXEL_PLAN_MONTHLY_MAINTENANCE_FOR_1_YEAR
- OP_IPILIMUMABNIVOLUMAB_MELANOMA
- OP_IPILIMUMABNIVOLUMAB_NSCLC
- OP_IPILIMUMABNIVOLUMAB_X4_FOLLOWED_BY_NIVOLUMAB_MONOTHERAPY_RENAL_CELL_CARCINOMA
- OP_IRINOTECANCETUXIMABVEMURAFENIB_EVERY_14_DAYS
- OP_IROX
- OP_ISATUXIMABCARFILZOMIBDEXAMETHASONE_IKEMA
- OP_IXABEPILONE
- OP_LAPATINIBCAPECITABINE
- OP_LIPOSOMAL_DOXORUBICIN_EVERY_14_DAYS
- OP_LIPOSOMAL_DOXORUBICIN_EVERY_28_DAYS
- OP_LIPOSOMAL_DOXORUBICINBEVACIZUMAB
- OP_LIPOSOMAL_IRINOTECANLEUCOVORINFLUOROURACIL
- OP_LONCASTUXIMAB_TESIRINE_LPYL_INITIAL_AND_MAINTENANCE_DOSE
- OP_LOW_DOSE_CYTARABINE_10_DAYS
- OP_LURBINECTEDIN
- OP_MARGETUXIMAB
- OP_MFOLFOX6_EVERY_14_DAYS
- OP_MFOLFOX6BEVACIZUMAB_EVERY_14_DAYS
- OP_MFOLFOX6CETUXIMAB_EVERY_14_DAYS
- OP_MFOLFOX6CETUXIMAB_EVERY_7_DAYS
- OP_MFOLFOX6NIVOLUMAB_EVERY_14_DAYS
- OP_MFOLFOX6PANITUMUMAB
- OP_MFOLFOX6ZIV_AFLIBERCEPT_EVERY_14_DAYS
- OP_MINE
- OP_MINICHOP
- OP_MIRVETUXIMAB_SORAVTANSINE_GYNX_EVERY_21_DAYS
- OP_MITOMYCIN_JELMYTO_FOR_PYELOCALYCEAL_INSTILLATION
- OP_MITOXANTRONEPREDNISONE
- OP_MODIFIED_CYBORDEX
- OP_MODIFIED_FOLFIRINOX_EVERY_2_WEEKS_FOR_PANCREATIC_CANCER_12_CYCLES
- OP_MOGAMULIZUMAB_EVERY_28_DAYS
- OP_MOXETUMOMAB_EVERY_28_DAYS
- OP_MVAC_DOSE_DENSE
- OP_NAB_PACLITAXEL
- OP_NAB_PACLITAXEL_EVERY_7_DAYS
- OP_NAB_PACLITAXELGEMCITABINE
- OP_NAB_PACLITAXELGEMCITABINE_DOSE_REDUCED
- OP_NIVOLUMAB_240_MG_FLAT_DOSE_EVERY_14_DAYS
- OP_NIVOLUMAB_3_MG_KG_EVERY_14_DAYS
- OP_NIVOLUMAB_480_MG_EVERY_28_DAYS
- OP_NIVOLUMAB_AND_RELATLIMAB
- OP_NON_MODIFIED_FOLFIRINOX_EVERY_2_WEEKS
- OP_O_FC
- OP_OBINUTUZUMAB
- OP_OBINUTUZUMAB_CYCLE_1_ONLY
- OP_OBINUTUZUMAB_CYCLE_2_6
- OP_OBINUTUZUMABBENDAMUSTINE_FOR_CLL_EVERY_28_DAYS
- OP_OBINUTUZUMABBENDAMUSTINE_FOR_NHL_EVERY_28_DAYS
- OP_OFATUMUMAB
- OP_OFATUMUMAB_EXTENDED_TREATMENT
- OP_OFATUMUMAB_REFRACTORY
- OP_PACLITAXEL_DOSE_DENSE
- OP_PACLITAXELCARBOPLATIN_AUC_2_EVERY_28_DAYS
- OP_PACLITAXEL_80_EVERY_7_DAYS
- OP_PAD
- OP_PANITUMUMAB
- OP_PEMBROLIZUMAB_FLAT_DOSE
- OP_PEMBROLIZUMAB_WEIGHT_BASED_MYCOSIS_FUNGOIDES_SÉZARY_SYNDROME
- OP_PEMBROLIZUMABCARBOPLATINPEMETREXED
- OP_PEMBROLIZUMABCARBOPLATIN_AUC_5FLUOROURACIL_CADD_EVERY_21_DAYS_HEAD_AND_NECK
- OP_PEMBROLIZUMABPACLITAXELCARBOPLATIN_AUC_5_EVERY_21_DAYS
- OP_PEMBROLIZUMAB_400_EVERY_42_DAYS
- OP_PEMETREXED
- OP_PENTOSTATIN
- OP_PHESGO_EVERY_21_DAYS
- OP_POLATUZUMABBENDAMUSTINERITUXIMAB_NHL
- OP_POMP
- OP_PRALATREXATE
- OP_PRO00036989_CNTY_101_SCREENING_PINGALI
- OP_PRO00037422_LU22SCREENING
- OP_PRO00037422_LU22TREATMENT
- OP_PROCARBAZINELOMUSTINEVINCRISTINE
- OP_R_CEOP
- OP_R_CHOP
- OP_R_CVP
- OP_R_EPOCH
- OP_R_ICE
- OP_R_MINICHOP
- OP_RAMUCIRUMAB_EVERY_14_DAYS
- OP_RAMUCIRUMABDOCETAXEL_EVERY_21_DAYS
- OP_RAMUCIRUMABPACLITAXEL_EVERY_28_DAYS
- OP_RESEARCHHILL_H_48389_ALTRUBIO_MULTIPLE_DOSE_PK_SUBJECTS
- OP_RESEARCHHILL_H_48389_ALTRUBIO_MULTIPLE_DOSE_RETREATMENT
- OP_RESEARCHHILL_H_48389_ALTRUBIO_MULTIPLE_DOSE_PHASE
- OP_RESEARCH_ALLOVIRRAMOS_KRANCE_ALVR106_H_47960_PART_A_DOSE_ESCALATION
- OP_RESEARCH_ALLOVIRRAMOS_KRANCE_ALVR106_H_47960_PART_A_DOSE_ESCALATION_SCREENING
- OP_RESEARCH_BMT_CTN_17031801_H_45408_DONOR
- OP_RESEARCH_BMT_CTN_1705_H_46470
- OP_RESEARCH_CTL_BESTA_H_46862
- OP_RESEARCH_CTL_H_43516_CARMEN
- OP_RESEARCH_CTL_H_43516_CARMEN_6_MONTH_FOLLOW_UP
- OP_RESEARCH_CTL_H_43516_CARMEN_ANNUAL_FOLLOW_UP
- OP_RESEARCH_CTL_H_43516_CARMEN_PROCURMENT
- OP_RESEARCH_H_42712_MAPSS
- OP_RESEARCH_H_43405_VISTA_FOLLOW_UP
- OP_RESEARCH_H_43405_VISTA_INFUSION
- OP_RESEARCH_H_43405_VISTA_PROCUREMENT_ORDERS
- OP_RESEARCH_H_44843_TETRAVI_STUDY
- OP_RESEARCH_H_47739_BAT_IT_FOLLOW_UP
- OP_RESEARCH_H_48440LULLA_ARTEMIS_BASELINE
- OP_RESEARCH_H_48440LULLA_ARTEMIS_FOLLOW_UP
- OP_RESEARCH_H_48440LULLA_ARTEMIS_INFUSION
- OP_RESEARCH_H_48440LULLA_ARTEMIS_SCREENING
- OP_RESEARCH_H47561_MSC_COVID_19
- OP_RESEARCH_PRO00020917_CHANG_DTP
- OP_RESEARCH_PRO00020917_DTP_ADJUVANT_CHANG
- OP_RESEARCH_PRO00021286_KAMAT_NRG_GY009_ARM_1
- OP_RESEARCH_PRO00021286_KAMAT_NRG_GY009_ARM_2
- OP_RESEARCH_PRO00021286_KAMAT_NRG_GY009_ARM_3
- OP_RESEARCH_PRO00022533_ZHANG_ABBVIE_M14_239
- OP_RESEARCH_PRO00023822BERNICKERCANOPY_N_ARM_1
- OP_RESEARCH_PRO00024042CHANG_CONVERT_HR_HER2_BREAST_CANCER_INTO_CBCV_ARM_1
- OP_RESEARCH_PRO00024042CHANG_CONVERT_HR_HER2_BREAST_CANCER_INTO_CBCV_ARM_2
- OP_RESEARCH_PRO00024042CHANG_CONVERT_HR_HER2_BREAST_CANCER_INTO_CBCV_ARM_3
- OP_RESEARCH_PRO00024042CHANG_CONVERT_HR_HER2_BREAST_CANCER_INTO_CBCV_ARM_4
- OP_RESEARCH_PRO00024075_B59_ADJUVANT_CONTINUATION_NIRAVATH
- OP_RESEARCH_PRO00024075_B59_NIRAVATH
- OP_RESEARCH_PRO00024662_NGM_120_STUDY_18_0402_PROTOCOL_A3
- OP_RESEARCH_PRO00024928_BR004_GEYER
- OP_RESEARCH_PRO00025235_FARACH_NRG_GY020
- OP_RESEARCH_PRO00025653_BERNICKER_4D_PHARMA_MRX0518_I_002
- OP_RESEARCH_PRO00026229_ABDELRAHIM_NAPOLI_3_ARM_1
- OP_RESEARCH_PRO00026229_ABDELRAHIM_NAPOLI_3_ARM_2
- OP_RESEARCH_PRO00026637KAMAT_GOG_3044_LAE002INT2001_ARM_1
- OP_RESEARCH_PRO00026637KAMAT_GOG_3044_LAE002INT2001_ARM_2
- OP_RESEARCH_PRO00026826_ML41734_ZHANG
- OP_RESEARCH_PRO00026860SHAH_PEVONEDISTAT_2002TAKEDA_RANDOMIZED_PHASE_2_ARM_A
- OP_RESEARCH_PRO00026860SHAH_PEVONEDISTAT_2002TAKEDA_VENETOCLAX_PLUS_AZACITIDINE_RANDOMIZED_PHASE_2_ARM_B
- OP_RESEARCH_PRO00026882_JAIN_A221602
- OP_RESEARCH_PRO00028602_INTEGRAL_NON_RESPONDERS
- OP_RESEARCH_PRO00028602_INTEGRAL_RESPONDERS
- OP_RESEARCH_PRO00028925_FULVESTRANT_PLUS_ABEMACICLIB_WITH_FULVESTRANT_RUN_IN_CHANG
- OP_RESEARCH_PRO00028925_FULVESTRANT_PLUS_ABEMACICLIB_WITHOUT_FULVESTRANT_RUN_IN_CHANG
- OP_RESEARCH_PRO00029142SATKUNASIVAM_ENFORTUMAB_VEDOTIN_PEMBROLIZUMAB_MK_3475_PHASE_3_ADJUVANT_ARM_A
- OP_RESEARCH_PRO00029142SATKUNASIVAM_ENFORTUMAB_VEDOTIN_PEMBROLIZUMAB_MK_3475_PHASE_3_NEOADJUVANT_ARM_A
- OP_RESEARCH_PRO00029142SATKUNASIVAM_GEMCITABINE_CISPLATIN_PHASE_3_NEOADJUVANT_ARM_B
- OP_RESEARCH_PRO00029646NIRAVATH_OLEMA_OP_1250_001_PHASE_II_MONOTHERAPY_STUDY_IN_ADULTS_WITH_ADVANCED_OR_METASTATIC_HR_POSITIVE__HER2_NEGATIVE_BREAST_CANCER_SCREENING
- OP_RESEARCH_PRO00029646NIRAVATH_OLEMA_OP_1250_001_PHASE_II_MONOTHERAPY_STUDY_IN_ADULTS_WITH_ADVANCED_OR_METASTATIC_HR_POSITIVE__HER2_NEGATIVE_BREAST_CANCER_TREATMENT
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_A_CHOICE_1
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_A_CHOICE_2
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_A_CHOICE_3
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_A_CHOICE_4
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_B_CHOICE_1
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_B_CHOICE_2
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_B_CHOICE_3
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_B_CHOICE_4
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_C_CHOICE_1
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_C_CHOICE_2
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_C_CHOICE_3
- OP_RESEARCH_PRO00029661_A081801_ZHANG_ARM_C_CHOICE_4
- OP_RESEARCH_PRO00029685_A011801_JAIN
- OP_RESEARCH_PRO00030489_HMCC_BR22_001_BASELINE_ASSESSMENTS_NIRAVATH
- OP_RESEARCH_PRO00030489_HMCC_BR22_001_NIRAVATH
- OP_RESEARCH_PRO00030489_HMCC_BR22_001_SCREENING_ASSESSMENTS_NIRAVATH
- OP_RESEARCH_PRO00031037_NCT04513717_ARM_1_HAQUE
- OP_RESEARCH_PRO00031037_NCT04513717_ARM_2_HAQUE
- OP_RESEARCH_PRO00031037_NCT04513717_ARM_3_HAQUE
- OP_RESEARCH_PRO00031037_NCT04513717_ARM_4_HAQUE
- OP_RESEARCH_PRO00031234ABDELRAHIM_TAS_120_202_COHORT_A_AND_B
- OP_RESEARCH_PRO00031234ABDELRAHIM_TAS_120_202_COHORT_A_AND_B_SCREENING
- OP_RESEARCH_PRO00031234ABDELRAHIM_TAS_120_202_COHORT_C
- OP_RESEARCH_PRO00031234ABDELRAHIM_TAS_120_202_COHORT_C_SCREENING
- OP_RESEARCH_PRO00031953_NRG_GY023_SINGH_ARM_1_REGIMEN_1
- OP_RESEARCH_PRO00031953_NRG_GY023_SINGH_ARM_1_REGIMEN_2
- OP_RESEARCH_PRO00031953_NRG_GY023_SINGH_ARM_1_REGIMEN_3_DAILY_TOPOTECAN
- OP_RESEARCH_PRO00031953_NRG_GY023_SINGH_ARM_1_REGIMEN_3_WEEKLY_TOPOTECAN
- OP_RESEARCH_PRO00031953_NRG_GY023_SINGH_ARM_2
- OP_RESEARCH_PRO00031953_NRG_GY023_SINGH_ARM_3
- OP_RESEARCH_PRO00031953_NRG_GY023_SINGH_ARM_4
- OP_RESEARCH_PRO00032239_ML43352_ABDELRAHIM
- OP_RESEARCH_PRO00032606_LOXO_BTK_20022_ARM_A_SHAH
- OP_RESEARCH_PRO00032606_LOXO_BTK_20022_ARM_B_SHAH
- OP_RESEARCH_PRO00032606_LOXO_BTK_20022_SHAH_ARM_A_BASELINE_SCREENING
- OP_RESEARCH_PRO00032606_LOXO_BTK_20022_SHAH_ARM_B_BASELINE_SCREENING
- OP_RESEARCH_PRO00032923_NCT04935359_ABDELRAHIM
- OP_RESEARCH_PRO00033015_ONC_392_001_CHANG
- OP_RESEARCH_PRO00033015_ONC_392_001_SCREENING_CHANG
- OP_RESEARCH_PRO00033043_CTO53_MM_02_LUMMICAR_STUDY_2_FOLLOW_UP_FOR_EARLY_WITHDRAWAL_GANGULY
- OP_RESEARCH_PRO00033043_CTO53_MM_02_LUMMICAR_STUDY_2_GANGULY
- OP_RESEARCH_PRO00034040ZAID_MERCK_MK_7684A_005_03_COHORT_A1_ARM_1
- OP_RESEARCH_PRO00034040ZAID_MERCK_MK_7684A_005_03_COHORT_A1_ARM_2
- OP_RESEARCH_PRO00034040ZAID_MERCK_MK_7684A_005_03_COHORT_A2_ARM_1
- OP_RESEARCH_PRO00034040ZAID_MERCK_MK_7684A_005_03_COHORT_B1_ARM_1
- OP_RESEARCH_PRO00034040_MERCK_MK_7684A_005_03_COHORT_IARM_8_DOCETAXEL_75_MG_PER_M2
- OP_RESEARCH_PRO00034040_MERCK_MK_7684A_005_03_COHORT_IARM_8_TAXOL_175_MG_PER_M2
- OP_RESEARCH_PRO00034040_MERCK_MK_7684A_005_03_COHORT_IARM_8_TAXOL_60_MG_PER_M2
- OP_RESEARCH_PRO00034040_MERCK_MK_7684A_005_03_COHORT_IARM_8_TAXOL_80_MG_PER_M2
- OP_RESEARCH_PRO00035089EFSTATHIOU_XL184_315_RANDOMIZED_PHASE_3_ABIRATERONE_WITH_PREDNISONE_NHT_CONTROL_ARM
- OP_RESEARCH_PRO00035089EFSTATHIOU_XL184_315_RANDOMIZED_PHASE_3_CABOZANTINIB_WITH_ATEZOLIZUMAB_EXPERIMENTAL_ARM
- OP_RESEARCH_PRO00035089EFSTATHIOU_XL184_315_RANDOMIZED_PHASE_3_ENZALUTAMIDE_NHT_CONTROL_ARM
- OP_RESEARCH_PRO00035089EFSTATHIOU_XL184_315_RANDOMIZED_PHASE_3_SAFETY_EVALUATION_VISITS
- OP_RESEARCH_PRO00035089EFSTATHIOU_XL184_315_RANDOMIZED_PHASE_3_SCREENING
- OP_RESEARCH_PRO00035094SHAH_NS_018_201_NS_PHARMA_PHASE_2B_RANDOMIZED__CONTROLLED_2_ARM_STUDY_ARM_A
- OP_RESEARCH_PRO00035094SHAH_NS_018_201_NS_PHARMA_PHASE_2B_RANDOMIZED__CONTROLLED_2_ARM_STUDY_BAT_ARM_B
- OP_RESEARCH_PRO00035094SHAH_NS_018_201_NS_PHARMA_PHASE_2B_RANDOMIZED__CONTROLLED_2_ARM_STUDY_SCREENING
- OP_RESEARCH_PRO00035654_NCT04071457_GANGULY_ARM_1A_STEP_3
- OP_RESEARCH_PRO00035654_NCT04071457_GANGULY_ARM_2A_STEP_3
- OP_RESEARCH_PRO00035654_NCT04071457_GANGULY_PRE_REGISTRATION_STEP_1
- OP_RESEARCH_PRO00035655GANGULY_EAA173_DARATUMUMAB_HYALURONIDASE_SC_LENALIDOMIDE_DEXAMETHASONE_ARM_A
- OP_RESEARCH_PRO00035655GANGULY_EAA173_DARATUMUMAB_HYALURONIDASE_SC_LENALIDOMIDE_DEXAMETHASONE_SCREENING
- OP_RESEARCH_PRO00035655GANGULY_EAA173_LENALIDOMIDE_DEXAMETHASONE_ARM_B
- OP_RESEARCH_PRO00035735_ANHL1931_PINGALI_ARM_CE
- OP_RESEARCH_PRO00035735_ANHL1931_PINGALI_ARM_DF
- OP_RESEARCH_PRO00035735_ANHL1931_SCREENING_PINGALI
- OP_RESEARCH_PRO00035972ZHANG_ALX_ONCOLOGY_PEMBROLIZUMAB_ARM_1
- OP_RESEARCH_PRO00035972ZHANG_ALX_ONCOLOGY_PEMBROLIZUMAB_ARM_2
- OP_RESEARCH_PRO00035972ZHANG_ALX_ONCOLOGY_PEMBROLIZUMAB_SAFETY_LEAD_IN
- OP_RESEARCH_PRO00035972ZHANG_ALX_ONCOLOGY_SCREENING
- OP_RESEARCH_PRO00035973_NCT04675333_ARM_1_ZHANG
- OP_RESEARCH_PRO00035973_NCT04675333_ARM_2_ZHANG
- OP_RESEARCH_PRO00035973_NCT04675333_LEAD_IN_ZHANG
- OP_RESEARCH_PRO00035973_NCT04675333_SCREENING_ZHANG
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_MAINTENANCE_SHAH
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_PRIOR_TO_ALLOGENIC_HCT
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_STEP_0_PRE_REGISTRATION_SHAH
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_STEP_1_REGISTRATION_PRE_INDUCTIONARM_ASTEP_2_RANDOMIZATION_SHAH
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_STEP_3_PRE_REGISTRATION_SHAH
- OP_RESEARCH_PRO00036193_ARM_A_MMY3002_GANGULY
- OP_RESEARCH_PRO00036193_ARM_B_MMY3002_GANGULY
- OP_RESEARCH_PRO00036193_ARM_C_MMY3002_GANGULY
- OP_RESEARCH_PRO00036193_MMY3002_SCREENING_GANGULY
- OP_RESEARCH_PRO00036218_BAYER_21516_EFSTATHIOU
- OP_RESEARCH_PRO00036218_BAYER_21516_SCREENINGBASELINE_EFSTATHIOU
- OP_RESEARCH_PRO00036219EFSTATHIOU_I3Y_MC_JPEG_CYCLONE_3_PHASE_3_EXPERIMENTAL_ARM_ABEMACICLIB_LY2835219_ABIRATERONE_PREDNISONECONTROL_ARM_PLACEBO_ABIRATERONE_PREDNISONE
- OP_RESEARCH_PRO00036219EFSTATHIOU_I3Y_MC_JPEG_CYCLONE_3_PHASE_3_SCREENING
- OP_RESEARCH_PRO00036449RAMSHESH_NRG_BR007_ENDOCRINE_THERAPY_RT_PHASE_III_ARM_1
- OP_RESEARCH_PRO00036449RAMSHESH_NRG_BR007_ENDOCRINE_THERAPY_ONLY_PHASE_III_ARM_2
- OP_RESEARCH_PRO00036449RAMSHESH_NRG_BR007_PHASE_III_SCREENING
- OP_RESEARCH_PRO00036844EFSTATHIOU_AZD5305_WITH_ABIRATERONE_ACETATE_OPEN_LABEL_PHASE_I_IIA_PETRANHA_ARM_2
- OP_RESEARCH_PRO00036844EFSTATHIOU_AZD5305_WITH_DAROLUTAMIDE_OPEN_LABEL_PHASE_I_IIA_PETRANHA_ARM_3
- OP_RESEARCH_PRO00036844EFSTATHIOU_AZD5305_WITH_ENZALUTAMIDE_OPEN_LABEL_PHASE_I_IIA_PETRANHA_ARM_1
- OP_RESEARCH_PRO00036844EFSTATHIOU_AZD5305_WITH_HORMONAL_AGENTS_OPEN_LABEL_PHASE_I_IIA_PETRANHA_SCREENING
- OP_RESEARCH_PRO00036985_NCT05132504_POST_SURGERY_ESNAOLA
- OP_RESEARCH_PRO00036985_NCT05132504_PRE_SURGERY_ESNAOLA
- OP_RESEARCH_PRO00036985_NCT05132504_SCREEING_ESNAOLA
- OP_RESEARCH_PRO00037014SHAH_BMS_CA055_026_AZACITIDINE_RANDOMIZED_SCREENING
- OP_RESEARCH_PRO00037014SHAH_BMS_CA055_026_RANDOMIZED_AZACITIDINE
- OP_RESEARCH_PRO00037014SHAH_BMS_CA055_026_RANDOMIZED_AZACITIDINE_EXTENSION_PHASE
- OP_RESEARCH_PRO00037085_D926XC00001_ARM_1_MAI
- OP_RESEARCH_PRO00037085_D926XC00001_ARM_2_MAI
- OP_RESEARCH_PRO00037085_D926XC00001_ARM_3_MAI
- OP_RESEARCH_PRO00037085_D926XC00001_SCREENING_MAI
- OP_RESEARCH_PRO00037462_ADM00022216_PHASE_1_PART_B_ZHANG
- OP_RESEARCH_PRO00037489SATKUNASIVAM_PEMBROLIZUMAB_MK_3475_AND_PEMBROLIZUMAB_FOR_NMIBC_UNRESPONSIVE_TO_BCG_PHASE_II_COHORT_C_ARM_1
- OP_RESEARCH_PRO00037489SATKUNASIVAM_PEMBROLIZUMAB_MK_3475_AND_PEMBROLIZUMAB_FOR_NMIBC_UNRESPONSIVE_TO_BCG_PHASE_II_COHORT_C_ARM_2
- OP_RESEARCH_PRO00037521_NCT05609968_MK_3475_ARM_1_ZHANG
- OP_RESEARCH_PRO00037521_NCT05609968_MK_3475_ARM_2_ZHANG
- OP_RESEARCH_PRO00037521_NCT05609968_MK_3475_SCREENING_ZHANG
- OP_RESEARCH_PRO00037588_IOV_GM1_201_BASELINE_GANGULY
- OP_RESEARCH_PRO00037588_IOV_GM1_201_FUPEOALTFUEOA_GANGULY
- OP_RESEARCH_PRO00037588_IOV_GM1_201_SCREENING_GANGULY
- OP_RESEARCH_PRO00037588_IOV_GM1_201_TUMOR_HARVEST_GANGULY
- OP_RESEARCH_PRO00037627GANGULY_P_BCMA_ALL01_OPEN_LABEL__PHASE_I_SCREENING_AND_BASELINE
- OP_RESEARCH_PRO00037679ZHANG_EA5182_FOR_PATIENTS_WITH_METASTATIC_EGFR_MUTANT_NON_SMALL_CELL_LUNG_CANCER_NSCLC_RANDOMIZED_SCREENING
- OP_RESEARCH_PRO00037679ZHANG_EA5182_OSIMERTINIB_AZD9291_FOR_PATIENTS_WITH_METASTATIC_EGFR_MUTANT_NON_SMALL_CELL_LUNG_CANCER_NSCLC_RANDOMIZED_ARM_A
- OP_RESEARCH_PRO00037679ZHANG_EA5182_OSIMERTINIB_AZD9291_WITH_BEVACIZUMAB_FOR_PATIENTS_WITH_METASTATIC_EGFR_MUTANT_NON_SMALL_CELL_LUNG_CANCER_NSCLC_RANDOMIZED_ARM_B
- OP_RESEARCH_PRO00037682_S2302_SWOG_ARM_B
- OP_RESEARCH_PRO00037682_S2302_SWOG_SCREENING_BASELINE
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_1B_Q2W_EVERY_2_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_1B_Q4W_EVERY_4_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_1C
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_2A_Q2W_EVERY_2_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_2A_Q4W_EVERY_4_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_2B_Q2W_EVERY_2_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_2B_Q4W_EVERY_4_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_SCREENING
- OP_RESEARCH_PRO00037739SHAH_CABL001AUS08_PHASE_II_FOR_CHRONIC_MYELOGENOUS_LEUKEMIA_ASC2ESCALATE
- OP_RESEARCH_PRO00037739SHAH_CABL001AUS08_PHASE_II_FOR_CHRONIC_MYELOGENOUS_LEUKEMIA_ASC2ESCALATE_SCREENING
- OP_RESEARCH_PRO00037762HMCC_HM22_001_ATRA_ARM_1
- OP_RESEARCH_PRO00037762HMCC_HM22_001_ATRA_SCREENINGBASELINE
- OP_RESEARCH_PRO00037808_D361DC00001_SUN_ARM_A
- OP_RESEARCH_PRO00037808_D361DC00001_SUN_ARM_B
- OP_RESEARCH_PRO00037808_D361DC00001_SUN_SCREENING
- OP_RESEARCH_PRO00037831_ML44719_ABDELRAHIM_ARM_A
- OP_RESEARCH_PRO00037831_ML44719_ABDELRAHIM_ARM_B
- OP_RESEARCH_PRO00037831_ML44719_ABDELRAHIM_SCREENING
- OP_RESEARCH_PRO00037834_IDE196_002IND_143026_MAQSOOD_PHASE_2A_ARM_1
- OP_RESEARCH_PRO00037834_IDE196_002IND_143026_MAQSOOD_PHASE_2A_ARM_2
- OP_RESEARCH_PRO00037834_IDE196_002IND_143026_MAQSOOD_PHASE_2A_CHEMOTHERAPY_ARM_3_COMPARATOR_ARM
- OP_RESEARCH_PRO00037834_IDE196_002IND_143026_MAQSOOD_PHASE_2B_AND_3_CHEMOTHERAPY_ARM_2_COMPARATOR_ARM
- OP_RESEARCH_PRO00037834_IDE196_002IND_143026_MAQSOOD_SCREENING
- OP_RESEARCH_PRO00037866DB_1303_O_3002_NIRAVATH_ARM_1
- OP_RESEARCH_PRO00037866DB_1303_O_3002_NIRAVATH_ARM_2_NAB_PACLITAXEL
- OP_RESEARCH_PRO00037866DB_1303_O_3002_NIRAVATH_ARM_2_PACLITAXEL
- OP_RESEARCH_PRO00037866DB_1303_O_3002_NIRAVATH_SCREENING
- OP_RESEARCH_PRO00037870SATKUNASIVAM_ADJUVANT_V940_MRNA_4157_RANDOMIZED_DOUBLE_BLIND_PHASE_2
- OP_RESEARCH_PRO00037922GANGULY_PFIZER_C1071032_ELOTUZUMAB__POMALIDOMIDE__DEXAMETHASONE_EPD_ARM_B
- OP_RESEARCH_PRO00037922GANGULY_PFIZER_C1071032_OPEN_LABEL_SCREENING
- OP_RESEARCH_PRO00037933MERCK_MK_2870_005_GOG_3095_ARM_1
- OP_RESEARCH_PRO00037933MERCK_MK_2870_005_GOG_3095_ARM_2_DOXORUBICIN
- OP_RESEARCH_PRO00037933MERCK_MK_2870_005_GOG_3095_ARM_2_PACLITAXEL
- OP_RESEARCH_PRO00037983_NCT05899608_SRREENING_ZHANG
- OP_RESEARCH_PRO00037983_NCT05899608_WITH_CARBOPLATIN_AUC_6ABRAXANE_ZHANG
- OP_RESEARCH_PRO00037983_NCT05899608_WITH_CARBOPLATIN_AUC_6PACLITAXEL_ZHANG
- OP_RESEARCH_PRO00037985ZHANG_J3M_MC_JZQB_BASELINESCREENING
- OP_RESEARCH_PRO00037985ZHANG_J3M_MC_JZQB_NON_SMALL_CELL_LUNG_ARM_A
- OP_RESEARCH_PRO00037985ZHANG_J3M_MC_JZQB_NON_SMALL_CELL_LUNG_ARM_B
- OP_RESEARCH_PRO00037985ZHANG_J3M_MC_JZQB_NON_SMALL_CELL_LUNG_ARM_B_SAFETY_LEAD
- OP_RESEARCH_PRO00037985ZHANG_J3M_MC_JZQB_PRE_SCREENING
- OP_RESEARCH_PRO00038042_61186372NSC2007HNJ_COCOON_ARM_A_ZHANG
- OP_RESEARCH_PRO00038042_61186372NSC2007HNJ_COCOON_ARM_B_ZHANG
- OP_RESEARCH_PRO00038042_61186372NSC2007HNJ_COCOON_SCREENING_ZHANG
- OP_RESEARCH_PRO0035580_BR22SCREENINGBASELINE
- OP_RESEARCH_PRO0035580_BR22TREATMENT
- OP_RESERACH_PRO00025711HEYNECA2099DW_BMS_ARM_A
- OP_RESERACH_PRO00025711HEYNECA2099DW_BMS_ARM_B
- OP_RITUXIMAB_WEEKLY_X4
- OP_RITUXIMABBORTEZOMIB
- OP_RITUXIMAB_375
- OP_RITUXIMAB_375_MAINTENANCE
- OP_RITUXIMAB_500
- OP_RITUXIMAB_INTRATHECAL_INTRAOMMAYA
- OP_ROMIDEPSIN
- OP_RSH_GO42784_NASBP_B_61_GIREDESTRANT_JAIN_ARM_A
- OP_RSH_GO42784_NASBP_B_61_GIREDESTRANT_JAIN_ARM_B
- OP_RSH_GO42784_NASBP_B_61_GIREDESTRANT_JAIN_SCREENING
- OP_RSH_PRO00026304_INFORM_STUDY_ABDELRAHIM
- OP_RSH_PRO00029151CMP_001_007_ZHANG_ARM_A
- OP_RSH_PRO00036001CA057_008_ARM_ACC_92480_CARFILZOMIB_DEXAMETHASONE
- OP_RSH_PRO00036001CA057_008_ARM_B_OPTION_1CARFILZOMIB_DEXAMETHASONE
- OP_RSH_PRO00036001CA057_008_ARM_B_OPTION_2CARFILZOMIB_DEXAMETHASONE
- OP_RSH_PRO00036001CA057_008_SCREENING
- OP_RSH_PRO00036343IMCGP100_203ARM_C
- OP_RSH_PRO00036354_SHILPAN_LOXO_BTK_20030_SCREENING
- OP_RSH_PRO00036423TT420C1206_ORAL_CHEMO
- OP_RSH_PRO00036423TT420C1206_SCREENING
- OP_RSH_PRO00036451_NAIR_ML43171_GIREDESTRANT_CONTROL_ARM_B
- OP_RSH_PRO00036451_NAIR_ML43171_GIREDESTRANT_EXPERIMENTAL_ARM_A
- OP_RSH_PRO00036451_NAIR_ML43171_GIREDESTRANT_SCREENING
- OP_RSH_PRO00037447_BN22_001_SBRT_TEH_SCREENING
- OP_RSH_PRO00037447_BN22_001_SBRT_TEH_TREATMENT_ARM
- OP_RSH_PRO00037490ARM_A_TAR_200_DEVICE_IV_CETRELIMAB
- OP_RSH_PRO00037694_ALLIANCE_A012103_JAIN_ARM_1_Q_42_DAYS
- OP_RSH_PRO00037694_ALLIANCE_A012103_JAIN_ARM_1_Q21_DAYS
- OP_RSH_PRO00037694_ALLIANCE_A012103_JAIN_ARM_2_OBSERVATION
- OP_RSH_PRO00037694_ALLIANCE_A012103_JAIN_SCREENING
- OP_RSH_PRO00037695HN009ARM_1_AND_3
- OP_RSH_PRO00037695HN009ARM_2_AND_4
- OP_RSH_PRO00037695HN009BASELINESCREENING
- OP_RSH_PRO00037748_ABDELRAHIM_CO44668_BOTH_ARMS
- OP_RSH_PRO00037748_ABDELRAHIM_CO44668_SCREENING
- OP_RSH_PRO00038015_TEMPLETON_TAXIS_PRE_TRIAL_PHASE
- OP_RSH_PRO00038015_TEMPLETON_TAXIS_TREATMENT_AND_FU_PHASE
- OP_SACITUZUMAB_GOVITECAN_HZIY
- OP_SALTZ
- OP_SIPULEUCEL_T_PROVENGE_EVERY_14_DAYS
- OP_TAC
- OP_TAFASITAMAB_CXIX
- OP_TAP
- OP_TC
- OP_TCH_LOADING_AND_MAINTENANCE_REGIMEN
- OP_TCH_LOADING_DOSE_ONLY
- OP_TCH_MAINTENANCE_REGIMEN
- OP_TECLISTAMAB_CQYV_MAINTENANCE
- OP_TEMSIROLIMUS_WEEKLY
- OP_TFOX_EVERY_2_WEEKS
- OP_TISOTUMAB_VEDOTIN_TFTV_EVERY_21_DAYS
- OP_TOPOTECAN_DAILY
- OP_TOPOTECAN_EVERY_7_DAYS
- OP_TOPOTECAN_WEEKLY
- OP_TOPOTECANBEVACIZUMAB
- OP_TOPOTECANBEVACIZUMAB_EVERY_7_DAYS
- OP_TRABECTEDIN_1.1_MG_PER_M2_NO_AMBULATORY_PUMP
- OP_TRABECTEDIN_1.5_MG_PER_M2_AMBULATORY_PUMP
- OP_TRASTUZUMAB_EVERY_21_DAYSPACLITAXEL_EVERY_7_DAYS_TRASTUZUMAB_MAINTENANCE_APT_TRIAL
- OP_TRASTUZUMAB_EVERY_21_DAYS_LOADING_AND_MAINTENANCE_DOSE
- OP_TRASTUZUMAB_EVERY_21_DAYS_LOADING_DOSE_ONLY
- OP_TRASTUZUMAB_EVERY_21_DAYS_MAINTENANCE_DOSE
- OP_TRASTUZUMAB_EVERY_7_DAYS
- OP_TRASTUZUMABCAPECITABINE_CYCLE_1_ONLY
- OP_TRASTUZUMABCAPECITABINE_CYCLE_2_AND_BEYOND
- OP_TRASTUZUMABCAPECITABINE_LOADING_AND_MAINTENANCE_REGIMEN
- OP_TRASTUZUMABLAPATINIB_CYCLE_1_ONLY
- OP_TRASTUZUMABLAPATINIB_CYCLE_2_AND_BEYOND_WEEKLY
- OP_TRASTUZUMABLAPATINIB_LOADING_AND_MAINTENANCE_REGIMEN
- OP_TRASTUZUMABOXALIPLATINLEUCOVORINFLUOROURACIL
- OP_TRASTUZUMABPACLITAXEL_EVERY_7_DAYS
- OP_TRASTUZUMABPERTUZUMAB_EVERY_21_DAYS_LOADING_AND_MAINTENANCE_DOSE
- OP_TRASTUZUMABPERTUZUMABDOCETAXEL_CYCLE_1_AND_CYCLE_2_4
- OP_TRASTUZUMABPERTUZUMABDOCETAXEL_CYCLE_1_ONLY
- OP_TRASTUZUMABPERTUZUMABDOCETAXEL_CYCLE_2_AND_BEYOND
- OP_TRASTUZUMABPERTUZUMABDOCETAXELCARBOPLATIN_LOADING_AND_MAINTENANCE_REGIMEN
- OP_TRASTUZUMABPERTUZUMABDOCETAXELCARBOPLATIN_LOADING_DOSE_ONLY
- OP_TRASTUZUMABPERTUZUMABDOCETAXELCARBOPLATIN_MAINTENANCE_REGIMEN
- OP_TRASTUZUMABPERTUZUMABPACLITAXEL_CYCLE_1_AND_CYCLE_2_6
- OP_TRASTUZUMABPERTUZUMABPACLITAXEL_CYCLE_1_ONLY
- OP_TRASTUZUMABPERTUZUMABPACLITAXEL_CYCLE_2_TO_6
- OP_TRASTUZUMAB_AND_HYALURONIDASE_EVERY_21_DAYS_MAINTENANCE
- OP_TREMELIMUMAB_ONCEDURVALUMAB_FLAT_DOSE_1500_MG_EVERY_28_DAYS_UNRESECTABLE_HEPATOCELLULAR_CARCINOMA
- OP_TVEC
- OP_VDC
- OP_VINCRISTINE
- OP_VINORELBINE_EVERY_7_DAYS
- OP_VIP
- OP_XELIRI_EVERY_21_DAYS
- OP_XELIRIBEVACIZUMAB_EVERY_14_DAYS
- OP_XELIRICETUXIMAB_EVERY_14_DAYS
- OP_XELIRICETUXIMAB_EVERY_7_DAYS
- OP_XELIRIPANITUMUMAB_EVERY_7_DAYS
- OP_XELIRIZIV_AFLIBERCEPT_EVERY_21_DAYS
- OP_XELOX_EVERY_21_DAYS
- OP_XELOXBEVACIZUMAB_EVERY_14_DAYS
- OP_XELOXBEVACIZUMAB_EVERY_21_DAYS
- OP_XELOXCETUXIMAB
- OP_XELOXCETUXIMAB_EVERY_14_DAYS
- OP_XELOXPANITUMUMAB
- OP_XELOXZIV_AFLIBERCEPT_EVERY_14_DAYS
- OP_IP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINEBREXUCABTAGENE_AUTOLEUCEL
- OP_IP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINECILTACABTAGENE_AUTOLEUCEL
- OP_IP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINEIDECABTAGENE_VICLEUCEL
- OP_IP_CAGT_CYCLOPHOSPHAMIDEFLUDARABINELISOCABTAGENE_MARALEUCEL
- OP_IP_EP_EMA
- OP_IP_EPCORITAMAB_BYSP
- OP_IP_PRO00036989_SCHEDULE_A_CNTY_101_PINGALI
- OP_IP_PRO00036989_SCHEDULE_B_CNTY_101_PINGALI
- OP_IP_RESEARCH_BMT_CTN_17031801_H_45408_PATIENT
- OP_IP_RESEARCH_CTL_H_43516_CARMEN
- RESARCH_PRO17492_DARCOURT_PHASE_1B_TRIAL_OF_L_NMMA_IN_COMBINATION_WITH_PEMBROLIZUMAB
- RESEARCHHILL_CTL_H_43761_CRIMSON_NE
- RESEARCHHILL_CTL_H_43761_CRIMSON_NE_FOLLOW_UP
- RESEARCHHILL_CTL_H_43761_CRIMSON_NE_PROCUREMENT_ORDERS
- RESEARCH_CATCH_H_49796_ARMAGHANY
- RESEARCH_CTL_GENERIC_BLOOD_COLLECTION_ORDERS
- RESEARCH_CTL_GENERIC_INFUSION_ORDERS
- RESEARCH_CTL_H_23574_CHARKALL
- RESEARCH_CTL_H_23574_CHARKALL_FOLLOW_UP_LABS_OP
- RESEARCH_CTL_H_24489_AHMED_HEROS
- RESEARCH_CTL_H_27471_CARRUM_TACTAL
- RESEARCH_CTL_H_29617_GRALE
- RESEARCH_CTL_H_29966_HESLOP_ARMS
- RESEARCH_CTL_H_29966_HESLOP_ARMS_FOLLOW_UP_LABS
- RESEARCH_CTL_H_31970_SAGAN
- RESEARCH_CTL_H_31973_AH_MED_ICAR
- RESEARCH_CTL_H_31973_AH_MED_ICAR_FOLLOW_UP_LABS_OP
- RESEARCH_CTL_H_32335_WANG_VEGAS
- RESEARCH_CTL_H_33133_RAMOS_CARPASCIO
- RESEARCH_CTL_H_33900_HESLOP_CITADEL
- RESEARCH_CTL_H_33903_CHARMS
- RESEARCH_CTL_H_33903_CHARMS_FOLLOW_UP_LABS
- RESEARCH_CTL_H_35101_NAIK_BELLICUM_BP_004U
- RESEARCH_CTL_H_35136_RAMOS_VIRALYM_A
- RESEARCH_CTL_H_35253_ROUCE_MABEL
- RESEARCH_CTL_H_35253_ROUCE_MABEL_FOLLOW_UP_LABS
- RESEARCH_CTL_H_35253_ROUCE_MABEL_T_CELL_INFUSION_ONLY
- RESEARCH_CTL_H_35425_HESLOP_TACTASOM
- RESEARCH_CTL_H_35626_LULLA_TACTAM
- RESEARCH_CTL_H_35885_NAIK_VIRALYM_B
- RESEARCH_CTL_H_35885_NAIK_VIRALYM_B_FOLLOW_UP_LABS
- RESEARCH_CTL_H_35887_OMER_VIRALYM_C
- RESEARCH_CTL_H_35887_OMER_VIRALYM_C_FOLLOW_UP_LABS
- RESEARCH_CTL_H_36021_HESTIA
- RESEARCH_CTL_H_36346_CARRUM_ADSPAM
- RESEARCH_CTL_H_37042_LULLA_STELLA
- RESEARCH_CTL_H_37966_RELY_30
- RESEARCH_CTL_H_37966_RELY_30_FOLLOW_UP_LABS_OP
- RESEARCH_CTL_H_37966_RELY_30_INITIAL_PROCUREMENT_ORDERS
- RESEARCH_CTL_H_37966_RELY_30_SECOND_PROCUREMENT_ORDERS
- RESEARCH_CTL_H_39090_PREVALE
- RESEARCH_CTL_H_39090_PREVALE_FOLLOW_UP_LABS_OP
- RESEARCH_CTL_H_39209_TACTIC_ADULT
- RESEARCH_CTL_H_39209_TACTIC_PROCUREMENT_ORDERS
- RESEARCH_CTL_H_40378_TACTOPS
- RESEARCH_CTL_H_40378_TACTOPS_PROCUREMENT_ORDERS
- RESEARCH_CTL_H_40466_MAGENTA
- RESEARCH_CTL_H_40466_MAGENTA_FOLLOW_UP_LABS_OP
- RESEARCH_CTL_H_44526_ANCHOR
- RESEARCH_CTL_H_46604_BESTA_DONOR_PROCUREMENT
- RESEARCH_GAIL_N_FOLLOW_UP_LABS
- RESEARCH_GAIL_N_PHASE_I
- RESEARCH_GAIL_N_T_CELL_INFUSION_ONLY
- RESEARCH_H_45118_DONOR_PROCUREMENT_FOR_THIRD_PARTY_MULTIVIRUS_SPECIFIC_T_CELL_LINES
- RESEARCH_LAPACT_PRO00013022_ABI_007_PANC_007_LEHANE_ARM_A_POST_INDUCTION_ABRAXANE_GEMCITABINE_D1_8_15_UNTIL_DISEASE_PROGRESSION_AUGUST_27__2014
- RESEARCH_LAPACT_PRO00013022_ABI_007_PANC_007_LEHANE_INDUCTION_ABRAXANE_GEMCITABINE_D1_8_15_AUGUST_27__2014
- RESEARCH_LULLA_GLYCAR_H_38942
- RESEARCH_PRO000022921SATKUNASIVAM_CA2099_NIVOLUMAB_OR_NIVOLUMAB_BMS_986205_PHASE_2_ARM_A_RANDOMIZED
- RESEARCH_PRO000022921SATKUNASIVAM_CA2099_NIVOLUMAB_OR_NIVOLUMAB_BMS_986205_PHASE_2_ARM_B_RANDOMIZED
- RESEARCH_PRO000022921SATKUNASIVAM_CA2099_NIVOLUMAB_OR_NIVOLUMAB_BMS_986205_PHASE_2_ARM_C_RANDOMIZED
- RESEARCH_PRO00005852_RTOG_0724_GOG_0724_ARM_1_KAMAT_CONCURRENT_WEEKLY_CISPLATIN_RAIDATION_BRACHYTHERAPY
- RESEARCH_PRO00005852_RTOG_0724_GOG_0724_ARM_2_KAMAT_CONCURRENT_WEEKLY_CISPLATIN_RT_BRACHY_WITH_PACLITAXEL_CARBOPLATIN_4CYCLES
- RESEARCH_PRO00008985_CHANG_BO27938_ARM_B_VERSION_5_07_09_2014
- RESEARCH_PRO00009452_BERNICKER_GALAXY_2_TRIAL_ARM_A_12_19_2014
- RESEARCH_PRO00010074_CHANG_TEAL_ARM_2_VERSION_5_02_06_2015
- RESEARCH_PRO00010459_PACRITINIB_200MG_BID_IYER_AMENDMENT_2_7_31_2014
- RESEARCH_PRO00010459_PACRITINIB_400MG_DAILY_IYER_AMENDMENT_2_7_31_2014
- RESEARCH_PRO00010820_BERNICKER_ABI_007_NSCL_003_INDUCTION_10_28_2014
- RESEARCH_PRO00010820_BERNICKER_ABI_007_NSCL_003_MAINTENANCE_10_28_2014
- RESEARCH_PRO00011277_GOG_0286B_KAMAT_PACLITAXELCARBOPLATIN_EVERY_21_D_METFORMIN_PLACEBO_DAILY_3_10_15
- RESEARCH_PRO00011685_NIRAVATH_L_NMMA_PLUS_DOCETAXEL
- RESEARCH_PRO00011897_NRG_LU001_CONCURRENT_CHEMOTHERAPY_RADIATION_ARM_A_PACLITAXEL_50_MG_M2CARBOPLATIN_AUC_2_WEEKLY_FOR_6_CYCLES_VERSION_5_7_15
- RESEARCH_PRO00012194_CHANG_EGF117165_ARM_B_TRASTUZUMAB_NAB_PACLITAXEL_03_26_2014
- RESEARCH_PRO00012194_CHANG_EGF117165_ARM_B_TRASTUZUMAB_PACLITAXEL_03_26_2014
- RESEARCH_PRO00012803_GOG0281_KAMAT_ARM_A_LETROZOLE_2.5_VERSION_9_08_22_2016
- RESEARCH_PRO00012803_GOG0281_KAMAT_ARM_A_PACLITAXEL_80_EVERY_7_DAYS_VERSION_9_08_22_2016
- RESEARCH_PRO00012803_GOG0281_KAMAT_ARM_A_PEGYLATED_LIPOSOMAL_DOXORUBICIN_40_VERSION_9_08_22_2016
- RESEARCH_PRO00012803_GOG0281_KAMAT_ARM_A_PEGYLATED_LIPOSOMAL_DOXORUBICIN_50_VERSION_9_08_22_2016
- RESEARCH_PRO00012803_GOG0281_KAMAT_ARM_A_TAMOXIFEN_20_VERSION_9_08_22_2016
- RESEARCH_PRO00012803_GOG0281_KAMAT_ARM_A_TOPOTECAN_4_VERSION_9_08_22_2016
- RESEARCH_PRO00013139_GOG3005_KAMAT_ARMS_1__2__3_CARBOPLATIN_PACLITAXEL_Q3_WEEKS_PLACEBO_VELIPARIB_FOLLOWED_BY_PLACEBO_VELIPARIB_MAINTENANCE_THERAPY
- RESEARCH_PRO00013139_GOG3005_KAMAT_ARMS_1__2__3_CARBOPLATIN_PACLITAXEL_WEEKLY_PLACEBO_VELIPARIB_FOLLOWED_BY_PLACEBO_VELIPARIB_MAINTENANCE_THERAPY
- RESEARCH_PRO00013982_MERCK_KEYNOTE_100_DARCOURT_COHORTS_A_AND_B_PEMBROLIZUMAB
- RESEARCH_PRO00014219_BASKIN_BEVACIZUMAB_SOC_ARM
- RESEARCH_PRO00014219_BASKIN_LOMUSTINE_SOC_ARM
- RESEARCH_PRO00014219_BASKIN_METRONOMIC_TEMOZOLOMIDE_DAILY_X_28_SOC_ARM
- RESEARCH_PRO00014219_BASKIN_TEMOZOLOMIDE_SOC_ARM
- RESEARCH_PRO00014219_BASKIN_TOCAGEN_TOCA_511_15_01_EXPERIMENTAL_ARM
- RESEARCH_PRO00014976_ENSIGN_BERNICKER_VERSION_7_11_13_2017
- RESEARCH_PRO00015001_TAK_659
- RESEARCH_PRO00015047_INCB_57643_IYER
- RESEARCH_PRO00015423_INCB39110_206_IYER
- RESEARCH_PRO00015851_NU15B08_CHANG_VERSION_3_01_11_2017
- RESEARCH_PRO00016419BERNICKER_EA5142_ADJUVANT_NIVOLUMAB
- RESEARCH_PRO00017710_NIRAVATH_REVIVE_ARM_1_VAGINAL_ESTROGEN_ARM
- RESEARCH_PRO00017710_NIRAVATH_REVIVE_ARM_2_REPLENS_ARM
- RESEARCH_PRO00019188_RANDHAWACALB001A2301
- RESEARCH_PRO00019585_DARCOURTBAY_1163877_CONTROL_ARM_DOCETAXEL_75_MG_M2_ONCE_EVERY_21_DAYS
- RESEARCH_PRO00019585_DARCOURTBAY_1163877_CONTROL_ARM_PACLITAXEL_175_MG_M2_ONCE_EVERY_21_DAYS
- RESEARCH_PRO00019585_DARCOURTBAY_1163877_RANDOMIZED_TO_ROGARATINIB_IN_CYCLE_1
- RESEARCH_PRO00019601_ABDELRAHIMIPSEN_MM_398_07_02_03
- RESEARCH_PRO00019886BERNICKER_M16_298_MERU_RANDOMIZED_TO_ROVALPITUZUMAB_TESIRINE_IN_CYCLE_1
- RESEARCH_PRO00019932_ABDELRAHIM_SWOG_S1610_ARM_1
- RESEARCH_PRO00019932_ABDELRAHIM_SWOG_S1610_ARM_2
- RESEARCH_PRO00019932_ABDELRAHIM_SWOG_S1610_ARM_3
- RESEARCH_PRO00020138CHANG_ESR_17_13153
- RESEARCH_PRO00020306RANDHAWA_CCAT_FORMA_2102_HEM_101_COMBINATION_COHORTS_4__5__6__8
- RESEARCH_PRO00020306RANDHAWA_CCAT_FORMA_2102_HEM_101_SINGLE_COHORTS_1__2__3__7
- RESEARCH_PRO00020361_RANDHAWAASTX727_02_RANDOMIZED_TO_ASTX727_IN_CYCLE_1
- RESEARCH_PRO00020361_RANDHAWAASTX727_02_RANDOMIZED_TO_DECITABINE_IN_CYCLE_1
- RESEARCH_PRO00020441_ABDELRAHIM_CCAT_REPLIMUNE_RPL_001_16_PHASE_1
- RESEARCH_PRO00020441_ABDELRAHIM_CCAT_REPLIMUNE_RPL_001_16_PHASE_2
- RESEARCH_PRO00020572_ABDELRAHIMSWOG_1613_ARM_2
- RESEARCH_PRO00020607SURI_TESARO_FIRST_ADJUVANT_3000_03_005_ENGOT_OV44
- RESEARCH_PRO00020607SURI_TESARO_FIRST_NEO_ADJUVANT_3000_03_005_ENGOT_OV44
- RESEARCH_PRO00020627_ZAID_NRG_GY006_ARM_1
- RESEARCH_PRO00020627_ZAID_NRG_GY006_ARM_2
- RESEARCH_PRO00020780_SINGH_INCMGA00012
- RESEARCH_PRO00020925_ABDELRAHIM_ASTELLAS_PH3_GLOW
- RESEARCH_PRO00021204_NIRAVATH_DS8201_A_U302
- RESEARCH_PRO00021233_HEYNE_XL_184_021
- RESEARCH_PRO00021342_NIRAVATH_DS8201_A_U303
- RESEARCH_PRO00021475ABDELRAHIMPANOVA_3
- RESEARCH_PRO00021476ABDELRAHIM_INCB_54828_302_INCYTE_TRIAL_ARM
- RESEARCH_PRO00021476ABDELRAHIM_INCB_54828_302_INCYTE_TRIAL_GEM_ARM
- RESEARCH_PRO00021842_DARCOURT_IMMU_132_06
- RESEARCH_PRO00021842_DARCOURT_IMMU_132_06_COHORT_3
- RESEARCH_PRO00021863ZHANGPACIFIC_4
- RESEARCH_PRO00021936ABDELRAHIM_TELOTRISTAT_LEXICON_PHASE_2
- RESEARCH_PRO00021957ESNAOLA_ML41440_NEO_ADJUVANT_ATEZOLIZUMAB_FOR_NON_METASTATIC_RESECTABLE_HIGH_RISK_CUTANEOUS_MELANOMA
- RESEARCH_PRO00022270ABDELRAHIMASTELLAS_ISN_8951_CL_5201_ARM_1
- RESEARCH_PRO00022270ABDELRAHIMASTELLAS_ISN_8951_CL_5201_ARM_2
- RESEARCH_PRO00022762_DARCOURT_DORA_ARM_A
- RESEARCH_PRO00022762_DARCOURT_DORA_ARM_B
- RESEARCH_PRO00022835CHANG_MCC_15_11083_T_CELL_IMMUNE_CHECKPOINT_INHIBITION_FOR_HER2_NEGATIVE_BREAST_CANCER_PHASE_2_NEO_ADJUVANT_TRIAL_OF_PEMBROLIZUMAB_AND_DECITIABINE_COHORT_A
- RESEARCH_PRO00022835CHANG_MCC_15_11083_T_CELL_IMMUNE_CHECKPOINT_INHIBITION_FOR_HER2_NEGATIVE_BREAST_CANCER_PHASE_2_NEO_ADJUVANT_TRIAL_OF_PEMBROLIZUMAB_AND_DECITIABINE_COHORT_B
- RESEARCH_PRO00022852BERNICKER_PISCES_TAVO_PLUS_ELECTROPORATION_WITH_PEMBROLIZUMAB_PHASE_2
- RESEARCH_PRO00022968KAMATNRG_GY018
- RESEARCH_PRO00023053RANDHAWA_ALLIANCE_A041501_PHASE_III_ARM_I
- RESEARCH_PRO00023053RANDHAWA_ALLIANCE_A041501_PHASE_III_ARM_II
- RESEARCH_PRO00023091NIRAVATH_IMMU_132_09_SACITUZUMAB_GOVITECAN_PHASE_3_ARM_A
- RESEARCH_PRO00023091NIRAVATH_IMMU_132_09_SACITUZUMAB_GOVITECAN_PHASE_3_ARM_B
- RESEARCH_PRO00025139PINGALI_SGN35_015_BRENTUXIMAB_VEDOTIN_PHASE_2_PART_E
- RESEARCH_PRO00025139PINGALI_SGN35_015_BRENTUXIMAB_VEDOTIN_PHASE_2_PART_F
- RESEARCH_PRO00025435PINGALI_SGN35_028_BRENTUXIMAB_VEDOTIN_PHASE_2_SINGLE_ARM
- RESEARCH_PRO00026231NIRAVATH_BO41843_ROCHE_PHASE_III_RANDOMIZED_DOUBLE_BLIND
- RESEARCH_PRO00027370NAIR_EA5163_S1709_INSIGNA_ARM_A_1ST_LINE
- RESEARCH_PRO00027370NAIR_EA5163_S1709_INSIGNA_ARM_A_2ND_LINE
- RESEARCH_PRO00027370NAIR_EA5163_S1709_INSIGNA_ARM_B_1ST_LINE
- RESEARCH_PRO00027370NAIR_EA5163_S1709_INSIGNA_ARM_B_2ND_LINE
- RESEARCH_PRO00027370NAIR_EA5163_S1709_INSIGNA_ARM_C_1ST_LINE_INDUCTION
- RESEARCH_PRO00027370NAIR_EA5163_S1709_INSIGNA_ARM_C_1ST_LINE_MAINTENANCE
- RESEARCH_PRO00029163JAIN_NSABP_B_60_DS8201_A_U305_PHASE_3_SCREENING
- RESEARCH_PRO00029163JAIN_NSABP_B_60_DS8201_A_U305_RANDOMIZED_PHASE_3_ARM_A
- RESEARCH_PRO00029163JAIN_NSABP_B_60_DS8201_A_U305_RANDOMIZED_PHASE_3_ARM_B
- RESEARCH_PRO00030861ZHANGNRG_LU005_ARM_1
- RESEARCH_PRO00030861ZHANGNRG_LU005_ARM_2
- RESEARCH_PRO00031036ZHANG_BGB_A317_A1217_301_ADVANTIG_301_ARM_A_OPTION_2_RANDOMIZED_PHASE_3_NON_SMALL_CELL_LUNG_CANCER
- RESEARCH_PRO00031036ZHANG_BGB_A317_A1217_301_ADVANTIG_301_ARM_B_OPTION_2_RANDOMIZED_PHASE_3_NON_SMALL_CELL_LUNG_CANCER
- RESEARCH_PRO00031036ZHANG_BGB_A317_A1217_301_ADVANTIG_301_ARM_C_OPTION_2_RANDOMIZED_PHASE_3_NON_SMALL_CELL_LUNG_CANCER
- RESEARCH_PRO00031036ZHANG_BGB_A317_A1217_301_ADVANTIG_301_SCREENING_OPTION_2_RANDOMIZED_PHASE_3_NON_SMALL_CELL_LUNG_CANCER
- RESEARCH_PRO17580_DARCOURT_SGN22E_001
- RESEARCH_PRO17598_NIRAVATH_OBESITY_STUDY_ARM_1
- RESEARCH_PRO17598_NIRAVATH_OBESITY_STUDY_ARM_2
- RESEARCH_PRO17598_NIRAVATH_OBESITY_STUDY_ARM_3
- RESEARCH_PRO18449_PATEL_SWOG_S1418BR006_ARM_1_OBSERVATION
- RESEARCH_PRO18449_PATEL_SWOG_S1418BR006_ARM_2_MK_3475_PEMBROLIZUMAB
- RESEARCH_PRO19178_NIRAVATHDS8201_A_U201_PART_1_DOSE_FINDING_AND_PART_2_STAGE
- RSH_IP_OP_PRO00036433SGN70_101TREATMENT
- RSH_OP_PRO00035986EA9152BASELINE_SCREENING
- RSH_OP_PRO00036433SGN70_101SCREENINGBASELINE
- RSH_OP_PRO00036788_CAMBRIA_1ARM_A
- RSH_OP_PRO00036788_CAMBRIA_1ARM_B_CAMIZESTRANT
- RSH_OP_PRO00036788_CAMBRIA_1SCREENING
- RSH_OP_PRO00037396_NRG_GY026ARM_1
- RSH_OP_PRO00037396_NRG_GY026ARM_2
- RSH_OP_PRO00037396_NRG_GY026ARM_3
- RSH_OP_PRO00037917BR23_001_ARM_1
- RSH_OP_PRO00037917BR23_001_ARM_2
- RSH_OP_PRO00037917BR23_001_SCREENING
- RSH_OP_PRO00038062_CAMBRIA_2ARM_A
- RSH_OP_PRO00038062_CAMBRIA_2ARM_B_CAMIZESTRANT
- RSH_OP_PRO00038062_CAMBRIA_2_SCREENING
- RSH_PRO00036343IMCGP100_203BASELINE_SCREENING
- RSH_PRO00037811_NCT05578976ARM_A
- RSH_PRO00037811_NCT05578976ARM_B
- RSH_PRO00037811_NCT05578976SCREENING
- THERAPEUTIC_APHERESIS_PHOTOPHERESIS
- HM_BARIATRIC_INFUSION
- CAGT_ECULIZUMAB_SOLIRIS_FOR_AHUS
- CAGT_BORTEZOMIB_VELCADE_INJECTION
- CAGT_ZOLEDRONIC_ACID_ZOMETA_INFUSION
- CAGT_IVIG_INFUSION
- CAGT_ECULIZUMAB_SOLIRIS_FOR_PNH
- CAGT_INTRAVENOUS_FLUID_IV
- CAGT_ALLO_DAILY_ORDERS
- CAGT_AUTO_DAILY_ORDERS
- CAGT_CLINIC_PROCEDURE_W_CONSCIOUS_SEDATION
- CAGT_COMMON_ORDERS
- CAGT_DONOR_LEUKOCYTE_INFUSION_DLI
- CAGT_FEMORAL_LINE_PLACEMENT_W_SCC_DONOR_CENTER
- CAGT_DONOR_EVALUATION_NMDP_SIBLING
- CAGT_POST_TRANSPLANT_IMMUNIZATIONS
- CAGT_NEUPOGEN_STEM_CELL_MOBILIZATION_DEFAULT_PT_SUPPLIED
- CAGT_STEM_CELL_MONITORING_DEFAULT_PT_SUPPLIED
- CAGT_MOZOBIL_STEM_CELL_MOBILIZATION
- CAGT_PRE_TRANSPLANT_WORKUP
- IVIG_INFUSION_0.5_GM_KG_FOR_KIDNEY_TRANSPLANT_MAX_70_GRAMS
- HEMODIALYSIS_THERAPY_PLAN
- TRANSIENT_HEMODIALYSIS_THERAPY_PLAN
- IVIG_BOOSTER_INFUSION
- HEPATITIS_B_IMMUNE_GLOBULIN_HBIG_INFUSION
- VALPROATE_SODIUM_DEPACON_INFUSION
- IRON_DEXTRAN_COMPLEX_INFED_INFUSION
- VEDOLIZUMAB_ENTYVIO_INFUSION
- SOLIRIS_FOR_AHUS_ECULIZUMAB
- PENTAMIDINE_NEBUPENT_INHALATION
- FERRIC_GLUCONATE_FERRLECIT_INFUSION
- CYCLOPHOSPHAMIDE_CYTOXAN_INFUSION
- ARANESP_DARBEPOETIN
- INTRAVENOUS_FLUID_IV_INFUSION
- DENOSUMAB_XGEVA_INJECTION
- ZOLEDRONIC_ACID_ZOMETA_INFUSION
- IRON_SUCROSE_COMPLEX_VENOFER_INFUSION
- BLANK_THERAPY_PLAN
- CEREZYME_IMIGLUCERASE_INFUSION
- BELATACEPT_NULOJIX_MAINTENANCE_INFUSION
- VITAMIN_B12_CYANOCOBALAMIN_INJECTION
- GOSERELIN_ZOLADEX_SQ_INJECTION
- LEUPROLIDE_LUPRON_DEPOT_IM_INJECTION_MALE
- SOLIRIS_FOR_PNH_ECULIZUMAB
- ROMIPLOSTIM_NPLATE_SQ_INJECTION
- FILGRASTIM_NEUPOGEN_SQ_INJECTION
- FILGRASTIM_ZARXIO_SQ_INJECTION
- OCTREOTIDE_DEPOT_SANDOSTATIN_LAR_IM_INJECTION
- LANREOTIDE_SOMATULINE_DEPOT_SQ_INJECTION
- PEGFILGRASTIM_JMDB_FULPHILA_SQ_INJECTION
- DEXAMETHASONE_DECADRON_INFUSION
- CENTRAL_VENOUS_CATHETER_MAINTENANCE
- DEFEROXAMINE_DESFERAL_INFUSION
- BACLOFEN_LIORESAL_INTRATHECAL_INJECTION_TRIAL
- THERAPEUTIC_PHLEBOTOMY
- PENTAMIDINE_PENTAM_INFUSION
- CRYOPRECIPITATE_TRANSFUSION
- FRESH_FROZEN_PLASMA_TRANSFUSION
- PLATELET_TRANSFUSION
- BLOOD_TRANSFUSION
- EPOETIN_ALFA_PROCRIT_INJECTION_NON_ONCOLOGY
- INFLIXIMAB_MAINTENANCE_INFUSION
- IVIG_BOOSTER_MULTI_DAY_INFUSION
- METHOTREXATE_IM_INJECTION_ONCE
- IVIG_INFUSION_1_GM_KG_FOR_KIDNEY_TRANSPLANT
- SOLUMEDROL_INDUCTION_500_MG_METHYLPREDNISOLONE
- CYCLOPHOSPHAMIDE_CYTOXAN_INFUSION_ONCE
- CAGT_PALIFERMIN_KEPIVANCE_INJECTION
- MICAFUNGIN_MYCAMINE_INFUSION
- CIDOFOVIR_VISTIDE_INFUSION_FOR_KIDNEY_TRANSPLANT
- SILTUXIMAB_SYLVANT_INFUSION
- MORPHINE_INTRATHECAL_INJECTION_TRIAL
- WINRHO_SDF_INJECTION
- CYTOMEGALOVIRUS_IMMUNE_GLOBULIN_CYTOGAM_INFUSION
- CIDOFOVIR_VISTIDE_INFUSION_FOR_CMV
- POST_SPLENECTOMY_IMMUNIZATIONS
- IVIG_BOOSTER_INFUSION_ST._JOHNS_DEFAULT_PT_SUPPLIED
- COSYNTROPIN_CORTROSYN_INJECTION
- GILENYA_FINGOLIMOD_FIRST_DOSE_PROTOCOL_DR._SIMPSON
- THERAPEUTIC_APHERESIS_LDL_APHERESIS
- THERAPEUTIC_APHERESIS_PLATELET_REDUCTION
- THERAPEUTIC_APHERESIS_RBC_EXCHANGE
- THERAPEUTIC_APHERESIS_THERAPEUTIC_PLASMA_EXCHANGE
- THERAPEUTIC_APHERESIS_WBC_REDUCTION
- STEM_CELL_DONOR_LYMPHOCYTE_COLLECTION
- RHOD_IMMUNE_GLOBULIN_RHOGAM_INJECTION
- USTEKINUMAB_STELARA_INDUCTION_INFUSION
- BASILIXIMAB_SIMULECT_INFUSION
- LEUPROLIDE_ELIGARD_SQ_INJECTION
- TOCILIZUMAB_ACTEMRA_INFUSION
- IVIG_INDUCTION_INFUSION_0.4_GM_KG_DAILY_X5
- IVIG_INDUCTION_INFUSION_0.6_GM_KG_DAILY_X4
- BELIMUMAB_BENLYSTA_INFUSION
- INFLIXIMAB_INFUSION
- IVIG_INFUSION_1_GM_KG_FOR_LUNG_TRANSPLANT
- IVIG_INFUSION_0.5_GM_KG_FOR_LUNG_TRANSPLANT
- SOLUMEDROL_INDUCTION_1000_MG_METHYLPREDNISOLONE
- SOLUMEDROL_INDUCTION_1250_MG_METHYLPREDNISOLONE
- SOLUMEDROL_BOOSTER_WEEKLY_1000_MG_METHYLPREDNISOLONE
- SOLUMEDROL_BOOSTER_MONTHLY_1000_MG_METHYLPREDNISOLONE
- ABATACEPT_ORENCIA_INFUSION
- GOLIMUMAB_SIMPONI_ARIA_INFUSION
- ZOLEDRONIC_ACID_RECLAST_INFUSION
- CERTOLIZUMAB_PEGOL_CIMZIA_INJECTION_400_MG
- PEGLOTICASE_KRYSTEXXA_INFUSION
- FERRIC_CARBOXYMALTOSE_INJECTAFER_750_MG_INFUSION
- FERUMOXYTOL_FERAHEME_510_MG_INFUSION
- PAMIDRONATE_AREDIA_INFUSION
- DENOSUMAB_PROLIA_INJECTION
- EPOETIN_ALFA_PROCRIT_INJECTION_ONCOLOGY
- BLOOD_&_PLATELET_TRANSFUSION
- RESEARCH_SCREENING_PRO0009707_MTG_REIC_PC003_MILES
- NEUROLOGY_ONLY_MIGRAINE_INFUSIONS
- INTRAVENOUS_ANTIBIOTICS_THERAPY_PLAN
- LEUPROLIDE_LUPRON_DEPOT_IM_INJECTION_FEMALE
- ACUTE_HYPERSENSITIVITY_GUIDELINES
- NATALIZUMAB_INFUSION_EVERY_4_WEEKS
- OCRELIZUMAB_OCREVUS_INFUSION
- NUSINERSEN_SPINRAZA_FOR_SPINAL_MUSCULAR_ATROPHY_SMA_LOADING_DOSE
- NUSINERSEN_SPINRAZA_FOR_SPINAL_MUSCULAR_ATROPHY_SMA_MAINTENANCE_DOSE
- USTEKINUMAB_STELARA_SUBCUTANEOUS_INJECTION_FOR_PSORIASIS
- PATISIRAN_ONPATTRO_INFUSION
- USTEKINUMAB_STELARA_SUBCUTANENOUS_INJECTION_FOR_CROHN_DISEASE_MAINTENANCE
- STANDARD_4_HOUR_IOHEXOL_OMNIPAQUE_CLEARANCE_FOR_MEASURING_GFR
- RITUXIMAB_RITUXAN_SMITH_1101_RHEUMATOLOGY
- ULTOMIRIS_FOR_PNH_RAVULIZUMAB_CWVZ
- CRIZANLIZUMAB_ADAKVEO_INFUSION
- INFLIXIMAB_DYYB_INFLECTRA_INFUSION
- LUSPATERCEPT_REBLOZYL_INJECTION_EVERY_3_WEEKS
- ORITAVANCIN_ORBACTIV_INFUSION
- TEPROTUMUMAB_INFUSION
- RITUXAN_PVVR_RUXIENCE_SMITH_1101
- CASIRIVIMAB_IMDEVIMAB_INFUSION
- EPTINEZUMAB_VYEPTI_INFUSION
- OUTPATIENT_ELECTROLYTE_REPLACEMENT
- DESMOPRESSIN_0.3_MCG_KG_INFUSION_FOR_STIMULATION_TEST_MAX_DOSE_20_MCG
- RETACRIT_EPOETIN_ALFA_EPBX
- ANIFROLUMAB_SAPHNELO_INFUSION
- AVALGLUCOSIDASE_ALFA_NGPT_INFUSION
- ORITAVANCIN_KIMYRSA_INFUSION
- RITUXIMAB_ABBS_TRUXIMA_SM_1101
- EFGARTIGIMOD_ALFA_INFUSION_VYVGART_OR_EFGARTIGIMOD_ALFA_AND_HYALURONIDASE_QVFC_SQ_INJECTION_VYVGART_HYTRULO
- VEDOLIZUMAB_ENTYVIO_INFUSION_LOADING_DOSE_ONLY
- BEVACIZUMAB_INFUSION_EVERY_21_DAYS
- DEGARELIX_SUBCUTANEOUS_INJECTION_LOADING_DOSE_ONLY
- DEGARELIX_SUBCUTANEOUS_INJECTION_LOADING_&_MAINTENANCE
- RISANKIZUMAB_RZAA_SKYRIZI_INFUSION
- GROWTH_HORMONE_SUPPRESION_TEST
- INCLISIRAN_LEQVIO_SUBCUTANEOUS_INJECTION
- GLUCAGON_STIMULATION_TEST
- DESMOPRESSIN_STIMULATION_TEST
- VUTRISIRAN_AMVUTTRA_SUBCUTANEOUS_INJECTION
- LONG_10_HOUR_IOHEXOL_OMNIPAQUE_CLEARANCE_FOR_MEASURING_GFR
- ROZANOLIXIZUMAB_RYSTIGGO_INFUSION
- BENRALIZUMAB_FASENRA_SQ_EVERY_4_WEEKS
- BENRALIZUMAB_FASENRA_SQ_EVERY_8_WEEKS_MAINTENANCE
- ROMOSOZUMAB_EVENITY_SQ_EVERY_4_WEEKS
- RESEARCH_PRO00024239_GABER_ISATUXIMAB_INFUSION
- CARFILZOMIB_KYPROLIS_FOR_AMR
- ETESEVIMAB_BAMLANIVIMAB_INFUSION
- RITUXIMAB_1000_MG_FOR_RHEUMATOLOGY
- RITUXIMAB_ABBS_TRUXIMA_375_MG_M2
- RITUXIMAB_ABBS_TRUXIMA_375_MG_M2_NEUROLOGY_RHEUMATOLOGY
- RITUXIMAB_ABBS_TRUXIMA_500_MG
- RITUXIMAB_ABBS_TRUXIMA_ONCE
- CASIRIVIMAB_IMDEVIMAB_SUBQ_INJECTION
- THYMOGLOBULIN_FOR_KIDNEY_TRANSPLANT_REJECTION
- FERUMOXYTOL_FERAHEME_1020_MG_INFUSION
- FERRIC_CARBOXYMALTOSE_INJECTAFER_15_MG_KG_INFUSION
- BEZLOTOXUMAB_ZINPLAVA_INFUSION
- MONOFERRIC_INFUSION
- OP_FULVESTRANT_INITIAL_AND_MAINTENANCE_INJECTION
- ADAMTS13_ADZYNMA_INFUSION
- SECUKINUMAB_COSENTYX_INFUSION
- ZOLEDRONIC_ACID_ZOMETA_INFUSION_EVERY_6_MONTHS
- HEMATOLOGY_LAB_THERAPY_PLAN
- LEQEMBI_10_MG_KG_INFUSION
- UPLIZNA_THERAPY_PLAN
- CYTOMEGALOVIRUS_IMMUNE_GLOBULIN_100_150_MG_KG_FOR_PANCREAS_TRANSPLANT
- BMT_CERT_EMERGENCY_ORDERS
- LEUPROLIDE_DEPOT_LUPRON_Q12WEEKS
- CAGT_POST_AUTOLOGOUS_STEM_CELL_TRANSPLANT_IMMUNIZATIONS
- TOCILIZUMAB_CABMR_INFUSION
- TOFERSEN_QALSODY_INTRATHECAL_INJECTION
- PEMIVIBART_PEMGARDA
v2.1